
Eskild Petersen

Content	Page
Personal data	2
<hr/>	
Academic degrees	2
Professor	
Doctor of Science	
Master of Business Administration	
Honorary Senior Lecturer, University College of London	
Diploma of Tropical Medicine and Hygiene (DTM&H)	
Medical Degree, University of Aarhus, Denmark	
<hr/>	
Postgraduate clinical training	2
Specialist of Tropical Medicine	
Specialist of Infectious Diseases	
Courses	
<hr/>	
Employments	
Research	3
Employment before specialization	
Employment after specialization	
<hr/>	
Teaching	3
<hr/>	
Scientific activities	
Publications	4
Books and book chapters	24
WHO-documents	
25	
Opponent at thesis and scientific reviews	
26	
Supervisor for PhD students	
Expert- and peer review activities	2
7	
Major research grants and research projects	
28	
International invited talks	30
<hr/>	
Administrative and organizational tasks	
Revision of candidate part, medical study, University of Aarhus	34
Editorial work	

Peer reviews for scientific journals	
35	
Scientific societies, membership and board membership	36
Advisory board	
Connect-Denmark, consultancy in biotech startup companies	3
7	
Danish Armed Forces, Consultant on Tropical Medicine	38
International meetings, member of the organizing committee	
Quality assurance, quality control	

Personal data

Name Eskild Petersen

Civil Registration No.

Marital status

Academic degrees

2015	Adjungated Professor of Tropical Medicine, Aarhus University, Denmark
2013	Professor of Tropical Medicine and Parasitology, Aarhus University
2005	Doctor of Science, DSc, Karolinska Institute, Stockholm. Diagnosis of infection with <i>Toxoplasma gondii</i> in pregnant women, neonates and immunocompromised patients
2002	Master of Business Administration, MBA, Scandinavian International Management Institute, SIMI, Copenhagen.
1980	Diploma in Tropical Medicine and Hygiene, DTM&H, Liverpool School of Tropical Medicine and Hygiene, University of Liverpool
1978	Medical Degree, University of Aarhus, Denmark

Honorary degrees

2018	Fellow of the International Society for Travel Medicine
2017	ESCMID Fellow
2009	Fellow of the Faculty of Travel Medicine, Royal College of Physicians and Surgeons of Glasgow. FFTM RCPS (Glasg)
2001 - 2006	Honorary Senior Lecturer, Department of Paediatric Epidemiology and Biostatistics, Institute of Child Health, University of London

Specialist degrees

1985 - 1988	Specialist of Tropical Medicine
1981 - 1985	Specialist of Infectious Diseases (Denmark and Sweden)
1978 - 1980	Internship

Theoretical training

August 2005	University teaching paedagogic course. Aarhus University, followed by 12 months project work with student evaluations and colleague coaching where two teachers evaluate each other over several months.
April 2005	Genetics of Complex Diseases, Karolinska Institute, Stockholm
Februar 2005	Biometrics and Genomics, Karolinska Institute, Stockholm
Januar 2005	Animals for Research, Karolinska Institute, Stockholm
Juli 1984	Intensive course in epidemiology, London School of Hygiene and Tropical Medicine.
Juli 1974	Course in Tropical Medicine, (Medical Summer School), American University of Beirut, Libanon.

Employments

Research positions

30.9.05 – 31.12.05	University of Aarhus, Research leave.
11.1985 - 10.1987	Research fellow, UNDP/World Bank/WHO Special Program on Research and Training in Tropical Diseases. Malaria Research Unit, Yekepa, Liberia administreret af Karolinska Institutet, Stockholm.

Employment after specialisation

1.02.19 – 31.01.20	Senior Advisor, Directorate General for Disease Surveillance and Control, Ministry of Health, Muscat, Oman. Special areas: the national plans for malaria, tuberculosis and travel medicine.
1.11.15 – 31.01.19	Senior Consultant, Infectious Diseases, The Royal Hospital, Muscat, Oman
15.10.03 – 31.10.15	Consultant, Department of Infectious Diseases, Aarhus University Hospital, Skejby
1.01.02 - 14.10.03	Head of Department and Consultant, Department of Gastrointestinales and Parasitic Infections, Statens Serum Institut, Copenhagen, Denmark
01.1999 – 12.2001	Head of Department and Consultant, Department of Mycobacterial and Parasitic Infections, Statens Serum Institut, Copenhagen, Denmark
06.1995-09.1995	Senior registrar, Department of Infectious Diseases, Hvidovre Hospital, Copenhagen, Denmark
01.1993 - 12.1998	Consultant and head, Laboratory of Parasitology, Statens Serum Institut, Copenhagen, Denmark
07.1989 - 12.1992	Consultant, Laboratory of Parasitology, Statens Serum Institut, Copenhagen, Denmark
01.01.88 - 07.31.1989	Senior Registrar, Department of Infectious Diseases, Roslagstull Hospital, Karolinska Institute, Stockholm, Sweden

Employment before specialisation

02.1981 - 08.1985	Clinical training in infectious diseases, Linköping University Hospital Sweden
07.1978 - 09.1980	Internship, Herning Central Hospital, Herning, Denmark

Teaching

2008 -	Course leader. "Infectious Diseases in a global perspective. Tropical Medicine and International Health". A 4 week course for pregraduate student at the 1. clinical term at medical school. Ten courses completed by 2019.
--------	---

2007	Postgraduate training course in research methodology for physicians.
2003 - 2015	Examination clinics for last semester medical students. Department of Infectious Diseases, Aarhus University Hospital, Aarhus Denmark.
2003 - 2019	Bedside teaching demonstrating patients.
2003 - 2015	Lectures for medical students at the Department of Infectious Diseases, Aarhus University Hospital, Aarhus. Two lectures per semester on malaria and gastrointestinal infections, pneumonia and malabsorption.
1995 - 2015	Lectures for medical students, Clinical Microbiology, University of Aarhus. Three hours symposium on parasitic infections (twice yearly).
1995 - 2015	Parasitology and tropical medicine for infectious disease specialists. One lecture per course appx. once per year.
1995 - 2015	Parasitology for specialists of clinical microbiology. One lecture per course appx. once per year.
1993 - 2015	Courses in Travelmedicine for general practitioners including, malaria, imported infections, SARS, emerging infections and travel immunisations.

Scientific activities

Publications

These publications are cited 5,236 times with an **H-index** of 49 (Scopus)
ORCID # 0000-0001-8510-0614

1. Høgh B & Petersen E. Planning of rural health projects in developing countries, with an example from Ngamiland, Botswana. *Ugeskr Læg* 1978,140,2469-73.
2. Petersen E & Høgh B. Pulmonary infiltration's with eosinophilia. Classification and differential diagnosis. *Ugeskr Læg* 1981,143,741-5.
3. Petersen E, Thorén G & Bergquist NR. Double infection with *Entamoeba histolytica* and *echinococcosis*. *Lancet* 1982,i,1132.
4. Petersen E, Thorén G & Bergquist NR. Mebendazole Treatment of *Echinococcus granulosus* infection. *Am J Trop Med Hyg* 1983,32,1071-4.
5. Høgh B & Petersen E. The basic health care system in Botswana: A study of the distribution and cost in the period 1973-1979. *Soc Sci Med* 1984,19,783-92.
6. Petersen E. ³H-hypoxanthine incorporation into fresh and stored blood: implications for resistance determination in *P. falciparum* malaria. *Ann Trop Med Parasit* 1986,80,251-2.
7. Berzins K, Perlmann H, Wåhlin B, Ruangjirachuporn W, Høgh B, Petersen E, Björkman A. & Perlmann P. Antibodies to repeated amino acid sequences in Pf 155, a merozoite associated antigen of *Plasmodium falciparum*. *Memorias do Instituto Oswaldo Cruz*, 1986,81(Suppl. II),77-81.
8. Petersen E. *In vitro* susceptibility of *Plasmodium falciparum* malaria to pyrimethamine, sulfadoxine, trimethoprim and sulfamethoxazole, singly and in combination. *Trans R Soc Trop Med Hyg* 1987,81,238-41.
9. Petersen E. Comparison of different methods for determining pyrimethamine susceptibility in *Plasmodium falciparum* malaria. *Ann Trop Med Parasitol* 1987,81,1-8.

10. Berzins K, Perlmann H, Wahlin B, Høgh B, Petersen E, Björkman A, Perlmann P. Isolation of human-antibodies to repeated sequences in the *Plasmodium falciparum* antigen Pf155. Scand J Immunol 1987;26:306
11. Perlmann H, Berzins K, Wahlin B, Hagstedt M, Andersson I, Høgh B, Petersen E, Björkman A, Perlmann P. Antibodies in human immune sera to amino-acid repeats in pf-155, a potential vaccine candidate antigen of the human malaria parasite *Plasmodium falciparum*. Scand J Immunol 1987;26:325.
12. Troye-Blomberg M, Kabilan I, Perlmann H, Petersen E, Høgh B, Björkman A, Perlmann P. Mapping of the *Plasmodium falciparum* antigen pf155 for T-cell reactive epitopes. Scand J Immunol 1987;26:332.
13. Petersen E, Høgh B, Hanson AP, Flachs H. Malaria breakthrough despite chlorproguanil prophylaxis in an area without anti-folate resistance. Trans R Soc Trop Med Hyg 1988,82,693.
14. Kabilan L, Troye-Blomberg M, Perlmann H, Andersson G, Høgh B, Petersen E, Björkman A, Perlmann P. T-cell epitopes in Pf155/RESA, a major candidate for a *Plasmodium falciparum* malaria vaccine. Proc Natl Acad Sci USA 1988,85,5659-63.
15. Troye-Blomberg M, Kabilan L, Riley EM, Örtlund J, Andersson G, Perlmann H, Olerup O, Høgh B, Petersen E, Snow RW, Björkman A, Greenwood BM, Perlmann P. T-cell reactivity of defined peptides from a major *Plasmodium falciparum* vaccine candidate: The Pf155/RESA antigen. Immunology Letters 1988,19,229-34.
16. Swedish Study Group. Therapy of acute and chronic Gram-negative osteomyelitis with ciprofloxacin. J Antimicrob Chemother 1988,22,221-8.
17. Hollingdale MR, Björkman A, Wirtz RA, Høgh B, Petersen E. Age dependent occurrence of protective anti-*Plasmodium falciparum* sporozoite antibodies in a holoendemic area of Liberia. Trans R Soc Trop Med Hyg 1989,83,322-4.
18. Petersen E, Høgh B, Perlmann H, Kabilan L, Troye-Blomberg M, Marbiah NT, Hanson AP, Björkman A, Perlmann P. An epidemiological study of humoral and cell-mediated immune response to the *Plasmodium falciparum* antigen Pf155/RESA in adult Liberians. Am J Trop Med Hyg 1989,41,394-402.
19. Perlmann H, Perlmann P, Berzins K, Wählin B, Troye-Blomberg M, Hagstedt M, Andersson I, Høgh B, Petersen E, Björkman A. Dissection of the human antibody response to the malaria antigen Pf155/RESA into epitope specific components. Immunol Rev 1989;112:115-32.
20. Björkman A, Perlmann H, Petersen E, Høgh B, Lebbad M, Warsame M, Hanson AP, Perlmann P. Consecutive determinations of sero-reactivities to Pf155/RESA antigen and to its different repetitive sequences in adult men from a holoendemic area of Liberia. Parasite Immunol 1990;12:115-23.
21. Petersen E, Høgh B, Marbiah NT, Perlmann H, Willcox M, Dolopaie E, Björkman A, Hanson AP, Coluzzi M, Perlmann P. A longitudinal study of Pf155/RESA antibodies and malaria infection in adult Liberians. Trans R Soc Trop Med Hyg 1990,84,339-45.
22. Petersen E, Høgh B, Hanson AP, Björkman A, Flachs H. *In vitro* and *in vivo* susceptibility of *Plasmodium falciparum* Isolates from Liberia to pyrimethamine, cycloguanil and chlorcycloguanil. Ann Trop Med Parasitol 1990,84,563-71.
23. Petersen E, Høgh B, Høj-Jakobsen P, Dziegel M, Borre M, Jepsen S. Malariavacciner, en nødvendighed for fremtidig malariakontrol. Ugeskr læg 1990,152,2092-5.
24. Petersen E, Høgh B, Bygbjerg IC, Black FT. Malaria chemoprophylaxis: Why mefloquine ? Lancet 1990;ii:811.
25. Björkman A, Lebbad M, Perlmann H, Freeman T, Høgh B, Petersen E, Gille E, Lindgren A, Willcox M, Hanson AP, Perlmann P. Longitudinal study of seroreactivities to Pf155/RESA and its

- repetitive sequences in small children from a holoendemic area of Liberia. *Parasite Immunol* 1991;13:301-11.
26. Petersen E, Flachs H, Høgh B, Hanson AP, Hvidberg EF. Human pharmacokinetics of chlorproguanil and its two main metabolites at different dose levels. *J Trop Med Hyg* 1991;94:199-205.
 27. Høgh B, Marbiah NT, Petersen E, Perlmann H, Dolopaie E, Hanson AP, Björkman A, Perlmann P. A longitudinal survey of antibodies to synthetic antigens of *Plasmodium falciparum* in infants and children living in a holoendemic area of Liberia. *Am J Trop Med Hyg* 1991;44:191-200.
 28. Berzins K, Perlmann H, Wåhlin B, Ekre HP, Høgh B, Petersen E, Schoenbechler M, Welde BT, Chulay JD, Perlmann P. Passive immunisation of *Aotus* monkeys with human antibodies to the *Plasmodium falciparum* antigen Pf155/RESA. *Infect Immun* 1991;59:1500-6.
 29. Petersen E, Borre M, Vuust J. Allele specific analysis of *Plasmodium falciparum* genes by the Polymerase Chain Reaction. *Mol Immunol* 1991;28:183-4.
 30. Dzielg M, Borre M, Jepsen S, Høgh B, Petersen E, Vuust J. *Plasmodium falciparum* glutamate rich protein produced in *Escherichia coli* as a fusion protein; Purification, application for enzyme linked immunosorbent assay, and prevalence of antibodies against β -galactoisidase. *Am J Trop Med Hyg* 1991;44:306-13.
 31. Petersen E, Høgh B, Marbiah N, Dolopaie E, Björkman A, Hanso AP. Clinical and parasitological immunity to malaria in Liberian adults living under intense malaria transmission. *Ann Trop Med Parasitol* 1991;85:577-84.
 32. Borre MB, Dzielg M, Høgh B, Petersen E, Rieneck K, Riley E, Meis J, Aikawa M, Nakamura K, Harada M, Wind A, Jakobsen PH, Cowland J, Jepsen S, Axelsen N, Vuust J. Primary structure and localization of a conserved immunogenic *Plasmodium falciparum* glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate life cycle. *Mol Biochem Parasitol* 1991;49:119-32.
 33. Petersen E, Høgh B, Marbiah NT, David K, Hanson AP. The development of parasitological and clinical immunity against *P.falciparum*: Clinical and parasitological immunity can not be separated. *J Infect Dis* 1991;164:949-53.
 34. Høgh B, Petersen E, Dzielg M, David K, Hanson AP, Jakobsen PH, Borre M, Holm A, Vuust J, Jepsen S. Antibodies to a recombinant glutamate-rich *Plasmodium falciparum* protein: indirect evidence for protection in individuals living in a holoendemic area of Liberia. *Am J Trop Med Hyg* 1992;46:307-13.
 35. Lebech M, Petersen E. Medfødt toksoplasmose og øjenaffektion (Congenital Toxoplasmosis and eye disease). *Ugeskr Læg* 1992;154:339-345.
 36. Lebech M, Lebech AM, Nelsing S, Vuust J, Mathiesen L, Petersen E. Detection of *Toxoplasma gondii* by polymerase chain reaction in cerebrospinal fluid from AIDS patients with Cerebral Toxoplasmosis. *J Infect Dis* 1992;165:982-3.
 37. Petersen E, Høgh B, Marbiah NT, Hanson AP. The effect of splenectomy on immunity to *Plasmodium malariae* and *Plasmodium falciparum* in a malaria immune donor. *Trop Med Parasitol* 1992;43:68-9.
 38. Petersen E, Høgh B, Dzielg M, Borre M, Björkman A, Marbiah NT, Dolopaie E, Hanson AP, Jepsen S. The antibody response to well defined malaria antigens in immune individuals. *Acta Tropica* 1992;51:135-42.
 39. Petersen E, Lebech M, Højlyng N, Holten-Andersen W, Mølbak K, Høgh B, Jepsen S. Parasitære infektioner hos patienter med nedsat immunforsvar (Parasitic infections in patients with a compromised immune system). *Ugeskr Læg*. 1992;154:2475-80.

40. Dziegiel M, Borre M, Petersen E, Høgh B, Jepsen S, Vuust J, Axelsen N. Capture ELISA for IgM antibodies against *Plasmodium falciparum* glutamate rich protein. J Immunol Method 1992,155,207-13.
41. Lebech M, Petersen E. Congenital toxoplasmosis. Scand J Inf Dis 1992 (Suppl. 84),1-114.
42. Lebech M, Petersen E. Neonatal screening for congenital toxoplasmosis in Denmark: Presentation of the design of a prospective study. Scand J Inf Dis 1992,84(Suppl.),75-79.
43. Høgh B, Marbiah NT, Petersen E, Dolopaye E, Willcox M, Hanson AP, Gottschau A. Malaria morbidity and chloroquine chemosuppression in infants and children living in a holoendemic area of Liberia. Acta Trop 1993;54:105-15.
44. Thorsen S, Rønne-Rasmussen J, Petersen E, Isager H, Seefeldt T, Mathiesen L. Extra intestinal amebiasis: Incidence and clinical presentation in a non-endemic setting. Scand J Infect Dis 1993;25:747-50.
45. Lebech M, Petersen E, Olesen-Larsen S. Prevalence, incidence and geographical distribution of antibodies against *Toxoplasma gondii* in pregnant women in Denmark. Scand J Infect Dis. 1993;25:751-6.
46. Højlyng N, Nielsen A, Wandahl J, Mølbak K, Blom J, Croft S, Petersen E. First cases of Microsporidiosis in Scandinavian Patients with AIDS. Scand J Infect Dis 1993,25,667-9.
47. Petersen E, Marbiah NT, Magbiti E, Lines JD, Maude G, Høgh B, Greenwood B, Bradley D. Controlled trial of lambda-cyhalothrin impregnated bed nets and Maloprim[®] chemosuppression in control of malaria in children living in a holoendemic area of Sierra Leone, West Africa. Study design and preliminary results. Parasitologia 1993,35,81-5.
48. Marbiah NT, Magbiti E, Lines JD, Curtis C, Maude GH, Greenwood BM, Bradley D, Petersen E. A double blind comparative study of the acceptability of untreated bed nets versus permethrin, deltamethin and lambda-cyhalothrin impregnated bed nets. Mem Inst Oswaldo Cruz 1994,89,5-9.
49. Høgh B, Petersen E, Crandall I, Gottschau A, Sherman IW. Immune reactivity to band-3 related neoantigens on *Plasmodium falciparum* infected erythrocytes. Infect Immun 1994,62,4362-6.
50. Petersen E, Marbiah NT. Comparison of the QBC[®] (Quantitative Buffer Coat) diagnostic system with thick blood films for malaria diagnosis under field conditions. Trans R Soc Trop Med Hyg 1994;88:416-7.
51. Petersen E, Ambroise-Thomas P, Foulon W, Gilbert R, Hedman K, Ho-Yen DO, Joynson DHM, Petithory JC, Stray-Pedersen B. Congenital Toxoplasmosis. The European research network on congenital toxoplasmosis. A concerted action under the EU research programme BIOMED1. J Obstet Gynaecol. 1994;14:112-7.
52. Lebech M, Petersen E. Detection of *Toxoplasma gondii* IgG-antibodies by Enzyme Immuno-Sorbent Assay from dried blood spots on PKU-filterpaper from new-borns. Scand J Infect Dis 1995,27,259-63.
53. Lebech M, Olesen Larsen S, Petersen E. Forekomsten af toksoplasmose hos gravide i Danmark. En undersøgelse af 5402 gravide (Toxoplasmosis in Danish pregnant women. A study of 5402 pregnancies). Ugeskrift Læg 1995,157,5242-5.
54. Petersen E. Prevention of congenital infection with *Toxoplasma gondii*. (Invited review). Neonatol. 1995,45:111-8.
55. Metsis A, Pettersen EK, Petersen E. Characterization of a monoclonal antibody recognizing two *Toxoplasma gondii* antigens of 38kDa and 36 kDa with acid phosphatase activity located in rhoptries and dense granules. Exp Parasitol 1995,81,472-9.

-
56. Ho-Yen DO, Dargie L, Chatterton JMW, Petersen E. Toxoplasma health education in Europe. *Health Educ J* 1995;54:415-20.
 57. Petithory JC, Reiter-Owona I, Berthelot F, Milgram M, De Loye J, Petersen E. Performance of European Laboratories testing serum samples for *Toxoplasma gondii*. *Eur J Clin Microbiol Infect Dis*. 1996;15:45-9.
 58. Harning D, Spenter H, Metsis A, Vuust J, Petersen E. Recombinant *Toxoplasma gondii* SAG1 (P30) expressed in *Escherichia coli* is recognized by human *Toxoplasma*-specific IgM and IgG antibodies. *Clin Diag Lab Immunol* 1996;3:355-7.
 59. Lebech M, Dutton G, Gilbert R, Øvlisen B, Petersen E, Seitz H, Thulliez P, Joynson DHM. Classification system and case definitions of *Toxoplasma*-infections in immunocompetent pregnant women and their congenitally infected offspring. *Eur J Clin Microbiol and Infec Dis* 1996;15:799-805.
 60. Petersen E, Marbiah NT, Gottschau A, New L. Comparison of two methods for enumerating malaria parasites in thick blood films. *Am J Trop Med Hyg* 1996;55:485-9.
 61. Guy E, Pelloux H, Lappalainen M, Aspöck H, Haßel A, Melby KK, Holberg-Pettersen M, Petersen E, Simon J, Ambroise-Thomas P. European Interlaboratory Comparison of PCR for the detection of *Toxoplasma gondii* in samples of artificially infected amniotic fluid. *Eur J Clin Microbiol Infect Dis* 1996;15:836-9.
 62. Dunn D, Gilbert R, Newell ML, Ades T, Petersen E, Peckham C and the European Collaborative Study. Low incidence of *Toxoplasma* infection in children born to women infected with human immunodeficiency virus. *Eur J Obstet Gyn Reprod Hlth* 1996;68:93-6.
 63. Eaton R, Petersen E, Seppänen H, Tuuminen T. A multi-centre evaluation of a fluorometric immunocapture assay to detect toxoplasma-specific IgM in newborn dried blood spots. *J Clin Microbiol* 1996;34:3147-50.
 64. Magbity EB, Marbiah NT, Maude G, Curtis CF, Bradley DB, Greenwood BM, Petersen E, Lines J. Effect of long term use of lambda-cyhalothrin impregnated bednets on *Anopheles gambiae* in Sierra Leone. *Med. Vet. Entomol.* 1997;11:79-86.
 65. David K, Marbiah NT, Nielsen PL, Lines J, Greenwood BM, Petersen E. Hyperpigmented maculae is seen as a side effect to fortnightly Maloprim[®] chemosuppression of malaria in West Africa. *Trans R Soc Trop Med Hyg* 1997;91:204-8.
 66. Smith JE, Boothroyd JC, Hunter C, Petersen E. Progress in Toxoplasmosis Research. *Parasitol Today* 1997;13:245-7. (Invited review)
 67. Petersen E. Malariaforebyggelse. Virkninger og bivirkninger af farmaka der bruges til forebyggelse af malaria (Malaria prophylaxis. Effect and side effects to drugs used for malaria prophylaxis). *Ugeskr Læg* 1997;159:2723-2730.
 68. Garly ML, Petersen E, Petersen C, Lundgren JD, Gerstoft J. Toxoplasmosis in Danish AIDS patients. *Scand J Infect Dis* 1997;27:597-600.
 69. David K, Petersen E, Arpi M. *Plasmodium falciparum* malaria in a pregnant women 6 months after last stat in a malarious area. (Danish). *Ugeskr Læg* 1998;160:4778-9.
 70. Marbiah NT, Petersen E, David K, Lines J, Magbity E, Bradley DB. Control of clinical malaria due to *Plasmodium falciparum* in children in an area of rural Sierra Leone with perennial transmission: A community-wide trial of lambda-cyhalothrin-impregnated mosquito nets alone and/or with fortnightly dapsone/pyrimethamine/placebo chemoprophylaxis. *Am J Trop Med Hyg* 1998;58:1-6.
 71. Petersen E, Spenter H, Nielsen HV. Immunisation with *E.coli* produced recombinant *Toxoplasma gondii* SAG1 with alum as adjuvant protect mice against lethal infection with *Toxoplasma gondii*. *Vaccine* 1998;16:1283-9.
-

-
72. Petersen E. Parasitære intestinale infektioner (Intestinal infections with parasites). Månedsskr Prak Læg 1998,76,1371-5.
 73. Jensen L, Petersen E, Henriksen SAa, Dietz HH, Lind P. Monoclonal antibodies to The *Toxoplasma gondii* strain 119, allocate all recently isolated Danish strains to one group. Intl J Parasitol: 1998,28:1305-13.
 74. Petersen E, Lebech M, Jensen L, Lind P, Rask M, Bagger P, Björkman C, Uggla A. Infection with *Neospora caninum* is not a major cause of habitual abortion in humans. Emerging Infectious Diseases 1999,5:278-80.
 75. Mølbak K, Petersen E, Böttiger B, Gerner-Smidt P. Rejsediarré - epidemiologi og ætiologi (Travellers diarrhoea – epidemiology and etiology). Månedsskr Prak Læg 1999,77,157-72.
 76. Lebech M, Andersen O, Christensen NC, Nielsen HE, Peitersen B, Rechnitzer C, Larsen SO, Nørgaard-Pedersen B, Petersen E & Danish Congenital Toxoplasmosis Study Group. Neonatal screening for congenital infection with *Toxoplasma gondii* in Denmark. Lancet 1999,353,1834-7.
 77. Dunn D, Wallon M, Peyron F, Petersen E, Gilbert R. Mother-to-child transmission of Toxoplasmosis: risk estimates for clinical counselling or risk estimates for clinical decision making. Lancet 1999,353:1829-33.
 78. Mølle I, Petersen E, Buhl M. Retrospective evaluation of exposure to *P.falciparum* using antibodies to the CircumSporozoite Protein and to cultured *P.falciparum* antigens. Scand J Infect Dis 1999,31:69-71.
 79. Lebech M, Petersen E. Neonatal screening for congenital toxoplasmosis (letter-reply). Lancet 1999,354:1030-1.
 80. Jungersen G, Jensen L, Riber U, Heegaard PMM, Petersen E, Dirch-Poulsen JS, Bille-Hansen V, Lind P. Pathogenicity of selected *Toxoplasma gondii* isolates in pigs. Int J Parasitol 1999,29:1307-19.
 81. Naessens A, Jenum P, Pollak A, Decoster A, Lappalainen M, Villena I, Petersen E, Stray-Pedersen B, Hayde M, Pinon JM, Lebech M, Foulon W. Diagnosis of congenital toxoplasmosis in the neonatal period. A multicentre evaluation. J Pediatrics 1999,135:714-9.
 82. Petersen E, Eaton R. Control of congenital infection with *Toxoplasma gondii* by neonatal screening based on detection of specific IgM-antibodies eluted from the PKU-filter paper. Acta Ped 1999, Suppl.432:36-9.
 83. Reiter-Owona I, Petersen E, Joynton DHM, Aspöck H, Dardé ML, Disko R, Dreazen O, Dumon H, Grillo R, Gross U, Hayde M, Holliman R, Ho-Yen DO, Janitschke K, Jenum P, Naser K, Olszewski M, Thulliez P, Seitz HM. Looking back on half a century of the Sabin-Feldman dye-test: its past and present role in the serodiagnosis of toxoplasmosis. Results of an European multicentre study. Bull WHO 1999;77:929-35.
 84. Nielsen HV, Fomsgaard A, Christainsen L, Petersen E. Complete protection against lethal *Toxoplasma gondii*-infection by a DNA-vaccine based on the *T.gondii* SAG1 gene. Infect Immun 1999,67:6358-63.
 85. Paul M, Petersen E, Pawlowski ZS, Szczapa J. Neonatal screening for anti-*Toxoplasma gondii* specific IgM antibodies in Poznan region (Poland) based on filter-paper blood cards as a valuable method for an early diagnosis of congenital infection. Ped Infect Dis J 2000;10:30-6.
 86. Petersen E, Rønne T, Rønn A, Bygbjerg IC, Olesen Larsen S. Reported side effects to chloroquine, chloroquine plus proguanil and mefloquine as chemoprophylaxis against malaria in Danish travellers. J Trav Med 2000;7:79-84.
 87. Tarp B, Black F, Petersen E. The immunofluorescence antibody test (IFAT) for the diagnosis of schistosomiasis used in a non-endemic area. Trop Med Intl Hlth 2000;5:185-91.

88. Cook, AJC, Gilbert R, Dunn, D., Buffolano, W., Zuffrey, J., Reymondin, M., Hohfeld, P., Foulon, W., Jenum, P., Petersen, E., Lebech, M., Semprini, E., Masters, J. Sources of toxoplasma-infection in pregnant women: a European multicentre case-control study. *Br Med J* 2000;312:142-7.
89. Høgdahl, E., Lind, P., Petersen, E. Development of a new typing system for *Toxoplasma gondii* based on the non-coding, repeat element TGR1E. *Intl J Parasitol* 2000;30:853-8.
90. Robert A, Luyasu V, Zuffrey J, Hedman K, Petersen E & European Network on Congenital Toxoplasmosis. Potential of the specific markers in the early diagnosis of Toxoplasma-infection: A multicentre study using combination of isotype IgG, IgM, IgA and IgE with values of avidity assay. *Eur J Clin Microbiol Infect Dis* 2001;20:467-74.
91. Petersen, E. Christian M.O. Kapel, Peter Deplazes. *Echinococcus multilocularis*: epidemiologi, klinik og behandling (*Echinococcus multilocularis*: epidemiology, clinical symptoms and treatment). *Ugeskr Læg* 2001,163:275-277.
92. Høgh B, Clarke PD, Camus D, Nothdruff HD, Overbosh D, Günter M, Joubert I, Kain KC, Shaw D, Roskell NS, Chulay JD & the Malarone International Study Team. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double blind study. *Lancet* 2000;356:1888-91.
93. Paul M, Jaworska A, Petersen E, Szczapa J, Twardosz-Pawlik H. Early evaluation of the postnatal treatment efficacy in infants with congenital toxoplasmosis from West Poland. *Intl J Parasitol* 2001;31:116-21.
94. Paul M, Petersen E, Szczapa J. Prevalence of congenital *T.gondii* infection in newborns from Poznan, Poland: validation of a combined screening by IgA/IgM ELISA. *J Clin Microbiol* 2001;39:1912-16.
95. Petersen E, Pollak A, Reiter-Owona I. Recent trends in research on congenital toxoplasmosis. *Int J Parasitol* 2001;31:115-144.
96. Gilbert, R., Dunn, D., Wallon, M., Hayde, M., Prusa, A., Lebech, M., Kortbeek, T., Peyron, F., Pollak, A., Petersen, E. Ecological comparison of the risks of mother-to-child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment period. *Epidemiol Infect* 2001;127:113-20.
97. Pinon JM, Dumon H, Chemla C, Franck J, Petersen E, Lebech M, Zufferey J, Bessieres M-H, Marty P, Holliman R, Johnson J, Luyasu V, Lecolier B, Guy E, Joynton DHM, Decoster A, Enders G, Pelloux H, Candolfi E. Strategy for diagnosis of congenital toxoplasmosis: Evaluation of methods comparing mothers and newborns and standard methods for postnatal detection of immunoglobulin G, M and A antibodies. *J Clin Microbiol* 2001;39:2267-71.
98. Sørensen T, Spenter J, Jaliashvili I, Christiansen M, Nørgaard-Pedersen B, Petersen E. An automated time-resolved immunofluometric assay for detection of *Toxoplasma gondii* specific IgM and IgA antibodies in filterpaper samples from newborns. *Clin Chemistry* 2002;48:1981-6.
99. Magbity EB, Magbity EB, Lines JD, Marbiah MT, David K, Petersen E. How reliable are light traps in estimating biting rates of adult *Anopheles gambiae* s.l. (Diptera: Culicidae) in the presence of treated bed nets? *Bull Entomol Res* 2002;92:71-6.
100. Enemark, HL, Ahrens, P, Juel CD, Petersen E, Petersen RF, Andersen JS, Lind P, Thamsborg SM. Molecular characterisation of Danish *Cryptosporidium parvum* isolates. *Int J Parasitol* 2002;125:331-41.
101. European Multicentre Study on Congenital Toxoplasmosis. Effect of timing and type of treatment on the risk of mother to child transmission of *Toxoplasma gondii*. *BJOG* 2003;110:112-20.
102. Petersen E. The safety of atovaquone/proguanil in long-term malaria prophylaxis of nonimmune adults. *J Travel Med.* 2003;10(Suppl 1):S13-5.

103. Petersen E, Schmidt DR. Sulfadiazine and pyrimethamine in the postnatal treatment of congenital toxoplasmosis: what are the options?. *Expert Rev Anti Infect Ther* 2003;1:175-82.
104. Kofoed K & Petersen E. The efficacy of chemoprophylaxis with chloroquine plus proguanil, mefloquine and atovaquone plus proguanil against malaria in travellers from Denmark. *J Travel Med.* 2003;10:150-4.
105. Couper KN, Nielsen HV, Petersen E, Roberts F, Roberts CW, Alexander J. DNA vaccination with the immunodominant tachyzoite surface antigen (SAG1) protects against adult acquired *Toxoplasma gondii* infection but does not prevent maternofetal transmission. *Vaccine.* 2003;21:2813-20.
106. Beghetto E, Buffolano W, Spadoni A, Pezza M del, Cristina M di, Minenkova O, Petersen E, Felici F, Gargano N. Diagnosis of primary *Toxoplasma gondii* infection in pregnancy by an IgG avidity assay based on recombinant antigens. *J Clin Microbiol* 2003;41:5414-8.
107. Petersen E. Malaria chemoprophylaxis: when should we use it and what are the options? *Expert Rev anti-Infect Ther* 2004;2:89-102.
108. Pietkiewicz H, Hyszczynska-Sawicka E, Kur J, Petersen E, Nielsen HV, Stankiewicz M, Andrzejewska I, Myjak P. Usefulness of *Toxoplasma gondii*-specific recombinant antigens in serodiagnosis of human toxoplasmosis. *J Clin Microbiol* 2004;42:1779-81.
109. Johannessen JK, Christiansen I, Schmidt DR, Petersen E, Hansen SH. Simultaneous determination of pyrimethamine, sulfadiazine and N-acetyl-sulfadiazine in plasma for monitoring infants in treatment of congenital toxoplasmosis. *J Pharm Biomed Anal* 2004;36:1093-8.
110. Damriyasa IM, Bauer C, Edelhofer R, Failing K, Lind P, Petersen E, Schres G, Tenter AM, Volmer R, Zahner H. Cross-sectional survey in pig breeding farms in Hesse, Germany: seroprevalence and risk factors of infections with *Toxoplasma gondii*, *Sarcocystis* spp. and *Neospora caninum* in sows. *Vet Parasitol* 2004;126:271-86.
111. Freeman K, Oakley L, Pollak A, Buffolano W, Petersen E, Semprini AE, Salt A, Gilbert R for the European Multicentre Study on Congenital Toxoplasmosis (EMSCOT). Association between congenital toxoplasmosis and preterm birth, low birthweight and small for gestational age. *Br J Obstet Gynaecol* 2005;112:31-7.
112. Beghetto E, Nielsen, HV, Del Poto P, Buffolano W, Guglietta S, Felici F, Petersen E, Gargano N. A combination of antigenic regions of *Toxoplasma gondii* microneme proteins induce protective immunity against oral infections with parasite cysts. *J Infect Dis* 2005;191:637-45.
113. Jensen C, Schiellerup P, Olsen KEP, Scheutz F, Petersen E, Gerner-Smidt P, Mølbak K. Management of asymptomatic carriers of Shiga toxin-producing *Escherichia coli*: to treat, or not to treat? *Scand J Infect Dis* 2005;37:61-3.
114. Bam, V, David, K, Odoi, A, Essegbey I, Petersen E, Browne E. Malaria control in pregnancy in Ghana. From research to policy. *Acta Tropica* 2005;95:S462-3.
115. Nielsen HV, Schmidt DR, Petersen E. Diagnosis of congenital toxoplasmosis by two-dimensional immunoblot differentiation of mother and child IgG-profiles. *J Clin Microbiol* 2005;43:711-5.
116. Møller LN, Petersen E, Kapel CM, Melbye M, Koch A. Outbreak of trichinellosis associated with consumption of game meat in West Greenland. *Vet Parasitol.* 2005;132:131-6.
117. Møller LN, Petersen E, Gamble HR, Kapel CM. Comparison of two antigens for demonstration of *Trichinella* spp. antibodies in blood and muscle fluid of foxes, pigs and wild boars. *Vet Parasitol* 2005;132:81-4.
118. Thalib L, Gras L, Romand S, Prusa A, Bessieres M-H, Petersen E, Gilbert RE, and The European Multicentre Study on Congenital Toxoplasmosis (EMSCOT). Prediction of congenital

- toxoplasmosis by polymerase chain reaction analysis of amniotic fluid. *Br J Obstet Gynaecol* 2005;112:567-74.
119. Petersen E, Borobio MV, Guy E, Liesenfeld O, Meroni V, Naessens A, Spranzi E, Thulliez P. European multicentre study of the LIAISON® automated diagnostic system for determination of specific IgG, IgM and IgG-avidity index in toxoplasmosis. *J Clin Microbiol*. 2005;43:1570-4.
 120. Salt A, Freeman K, Prusa A, Ferret N, Buffolano W, Malm G, Schmidt D, Tan HK, Gilbert RE, Petersen E; European Multicentre Study on Congenital Toxoplasmosis. Determinants of response to a parent questionnaire about development and behaviour in 3 year olds: European multicentre study of congenital toxoplasmosis. *BMC Pediatr*. 2005;5:21.
 121. Freeman K, Salt A, Prusa A, Malm G, Ferret N, Buffolano W, Schmidt D, Tan HK, Gilbert RE; European Multicentre Study on Congenital Toxoplasmosis. Association between congenital toxoplasmosis and parent-reported developmental outcomes, concerns, and impairments, in 3 year old children. *BMC Pediatr*. 2005;5:23.
 122. Olesen B, Neiman J, Böttiger B, Ethelberg S, Schiellerup P, Jensen C, Helms M, Scheutz F, Olsen KEP, Krogfelt K, Petersen E, Mølbak K, Gerner-Smidt P. Etiology of diarrhea in young children in Denmark: a case-control study. *J Clin Microbiol* 2005;43:3636-41.
 123. Petersen E. Travel Medicine internet resources (Danish). *Ugeskr Læg* 2005;167:3971-4.
 124. Buffolano W, Elisa Beghetto E, Del Pezzo M, Spadoni A, Manlio Di Cristina, Petersen E, Gargano N. The use of recombinant antigens for the early postnatal management of newborns with congenital toxoplasmosis. *J Clin Microbiol* 2005;43:5916-24.
 125. Freeman K, Salt A, Prusa A, Malm G, Ferret N, Buffolano W, Schmidt DR, Tan HK, Gilbert RE for The European Multicentre Study on Congenital Toxoplasmosis (EMSCOT). Association between congenital toxoplasmosis and parent-reported developmental outcomes, concerns, and impairments, in 3 year old children. *BMC Pediatr* 2005;5(23):1-22.
 126. Petersen E. Malaria chemoprophylaxis. *Ugeskr Læg* 2005;167:3984-7.
 127. Gras L, Wallon M, Pollak A, Cortina-Borja M, Evengard B, Hayde M, Petersen E, Ruth Gilbert R and The European Multicentre Study on Congenital Toxoplasmosis - Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. *Acta Paediatrica* 2005;94:1721-31.
 128. Schmidt DR, Høgh B, Andersen O, Honoré Hansen S, Dalhoff K, Petersen E. Treatment of infants with congenital toxoplasmosis: Tolerability and plasma concentrations of sulfadiazine and pyrimethamine. *Eur J Pediatr* 2006;165:19-25.
 129. Schmidt DR, Høgh B, Andersen O, Fuchs J, Fledelius H, Petersen E. The national neonatal screening programme for congenital toxoplasmosis in Denmark: Results from the initial 4 years 1999–2002. *Arch Dis Child* 2006;91:661-5.
 130. Petersen E, Edvinsson B, Lundgren B, Benfield T, Evengård B. Diagnosis of pulmonary infection with *Toxoplasma gondii* in immunocompromised HIV-positive patients by real-time PCR. *Eur J Clin Microbiol Infect Dis*. 2006;25:401-4.
 131. Nielsen HV, Di Christina M, Beghetto E, Spadoni A, Petersen E, Gargano N. *Toxoplasma gondii*: DNA vaccination with bradyzoite antigens induces protective immunity against oral infection with parasite cysts in mice. *Exp Parasitol* 2006;112:274-9.
 132. Peyron F, Lobry JR, Musset K, Ferrandiz J, Gomez-Marin JE, Petersen E, Meroni V, Rausher B, Mercier C, Picot S, Cesbron-Delauw MF. Serotyping of *Toxoplasma gondii* in chronically infected pregnant women: predominance of type II in Europe and types I and III in Colombia (South America). *Microbes Infect*. 2006;8:2333-40.
 133. Arendrup MC, O'driscoll BR, Petersen E, Denning DW. Acute pulmonary aspergillosis in immunocompetent subjects after exposure to bark chippings. *Scand J Infect Dis*. 2006;38:945-9.

-
134. Pietkiewicz H, Hiszczynska-Sawicka E, Kur J, Petersen E, Nielsen HV, Paul M, Stankiewicz M, Myjak P. Usefulness of *Toxoplasma gondii* recombinant antigens (GRA1, GRA7 and SAG1) in an immunoglobulin G avidity test for the serodiagnosis of toxoplasmosis. *Parasitol Res.* 2007;100:333-7.
 135. Jelinek T, Behrens R, Bisoffi Z, Bjorkmann A, Gascon J, Hellgren U, Petersen E, Zoller T; TropNetEurop, the European Network on Imported Infectious Disease, Andersen RH, Blaxhult A. Recent cases of falciparum malaria imported to Europe from Goa, India, December 2006-January 2007. *Euro Surveill.* 2007;12:1.
 136. Vesco G, Buffolano W, La Chiusa S, Mancuso G, Caracappa S, Chianca A, Villari S, Currò V, Liga F, Petersen E. *Toxoplasma gondii* infections in sheep in Sicily, southern Italy. *Vet Parasitol.* 2007;146:3-8.
 137. SYROCOT Study Group. Individual patient data meta-analysis of prenatal treatment effect for congenital toxoplasmosis. *Lancet* 2007;369:115-21
 138. Jamieson SE, De Roubaix LA, Cortina-Borja M, Tan HK, Mui E, Cordell HJ, Mack D, Kirisitsand M, Miller EN, Peacock CS, Hargrave A, Petersen E, McLeod R, Gilbert RE, Blackwell JM. Two ocular disease genes are epigenetically modified and associated with congenital toxoplasmosis. *Early Human Dev* 2007;83(Suppl.1):S98.
 139. Salamon SA, Fuursted K, Egeblad H, Petersen E, Ott P. *Candida albicans* tricuspidal and pulmonic valve endocarditis. Challenge of relapsing risk and role of combined medical therapy. *Scand J Infect Dis.* 2007;39:641-4.
 140. Møller LN, Andersen S, Melbye M, Petersen E, Laurbjerg P, Kapel CMO, Koch A. Risk factor analysis of *Trichinella* infection in Greenland. *Clin Microbiol Infect.* 2007;13:702-8.
 141. Gilbert RE, Petersen E, Thalib L, Gras L, Paul M, Wallon M, Evengard B, Hayde M, Tan HK for The European Multicentre Study on Congenital Toxoplasmosis (EMSCOT). Accuracy of IgM and IgA tests for congenital toxoplasmosis in early infancy: results from the European multicentre study. *J Med Screen.* 2007;14:8-13.
 142. Jamieson SE, De Roubaix LA, Cortina-Borja M, Tan HK, Mui E, Cordell HJ, Mack D, Kirisitsand M, Miller EN, Peacock CS, Hargrave A, Petersen E, McLeod R, Gilbert RE, Blackwell JM. Two ocular disease genes are epigenetically modified and associated with congenital toxoplasmosis *Early Human Dev* 2007;83:S98.
 143. Gollub EL, Leroy V, Gilbert R, Chêne G, Wallon M; European Toxoprevention Study Group (EUROTOXO). Effectiveness of health education on *Toxoplasma*-related knowledge, behaviour, and risk of seroconversion in pregnancy. *Eur J Obstet Gynecol Reprod Biol.* 2008;136:137-45.
 144. Petersen E. Toxoplasmosis. *Seminars in Fetal and Neonatal Medicine* 2007;12:214-23.
 145. Petersen E. Prevention and treatment of congenital toxoplasmosis. *Expert Rev Anti-Infect Ther:* 2007;5:285-93.
 146. Petersen E. Protozoan and helminth infections in pregnancy. Short-term and long-term implications of transmission of infection from mother to foetus. *Parasitology* 2007;134:1855-62.
 147. Freeman K, Tan HK, Prusa A, Petersen E, Buffolano W, Malm G, Cortina-Borja M, Gilbert R; European Multicentre Study on Congenital Toxoplasmosis. Predictors of retinochoroiditis in children with congenital toxoplasmosis: European, prospective cohort study. *Pediatrics* 2008;121:1215-22.
 148. Bénard A, Petersen E, Salamon R, Chêne G, Gilbert R, Salmi LR; European Toxo Prevention Study Group (EUROTOXO). Survey of European programmes for the epidemiological surveillance of congenital toxoplasmosis. *Euro Surveill.* 2008;13:15.
 149. Petersen E, Tolstrup M, Capuano F, Ellermann-Eriksen S. Population-based study of diagnostic assays for *Borrelia* infection: comparison of purified flagella antigen assay (Ideiatrade mark,

- Dako Cytomation) and recombinant antigen assay (Liaison(R), DiaSorin). BMC Clin Pathol 2008;8:4.
150. Jamieson SE, Roubaix LE de, Borja MC, Mui E, Mack D, Kirisitsand M, Miller EN, Cordell HJ, Petersen E, McLeod R, Gilbert RE, Blackwell JM for the European Multicentre Study on Congenital Toxoplasmosis (EMSCOT) and the USA/Canadian Toxoplasmosis Study Group. COL2A1 and ABCA4 are associated with ocular disease in congenital toxoplasmosis. PLoS ONE 2008;3(6):e2285.
 151. Gilbert RE, Freeman K, Lago EG, Bahia-Oliveira LM, Tan HK, Wallon M, Buffolano W, Stanford MR, Petersen E; for The European Multicentre Study on Congenital Toxoplasmosis (EMSCOT). Ocular Sequelae of Congenital Toxoplasmosis in Brazil Compared with Europe. PLoS Negl Trop Di. 2008;2:e277.
 152. Jongert E, Verhelst D, Abady M, Petersen E, Gargano N. Protective Th1 immune responses against chronic toxoplasmosis induced by a protein-protein vaccine combination but not by its DNA-protein counterpart. Vaccine 2008;26:5289-95.
 153. Schlagenhauf P, Petersen E. Malaria chemoprophylaxis: strategies for risk groups. Clin Microbiol Rev. 2008;21:466-72.
 154. Derouin F, Pelloux H; ESCMID Study Group on Clinical Parasitology. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect. 2008;14:1089-101.
 155. Nielsen US, Larsen CS, Howitz M, Petersen E. Hepatitis A among Danish travellers 1980-2007. J Infect. 2009;58:47-52.
 156. Stäger K, Legros F, Krause G, Low N, Smith V, Desai M, Graf S, D'Ámato A Yasutaka M, Janzon R, Petersen E, Kester J, Steffen R, Schlagenhauf P. Paediatric malaria imported to industrialised countries 1992 – 2002. Emer Infect Dis 2009;15:185-91.
 157. Vesco G, Buffolano W, La Chiusa S, Mancuso G, Caracappa S, Chianca A, Villari S, Currò V, Liga F, Petersen E. *Toxoplasma gondii* infections in sheep in Sicily, southern Italy. Veterinary Parasitol 2009; 161:1-8.
 158. Duus LV, Vittrup Christensen A, Navntoft D, Tarp B, Nielsen HV, Petersen E. The schistosoma-specific antibody response after treatment in non-immune travelers. Scand J Infect Dis 2009;41:285-90.
 159. Rosenberg C, De Craeye S, Jongert E, Gargano N, Beghetto E, Del Porto P, Vorup-Jensen T, Petersen E. Induction of partial protection against infection with *Toxoplasma gondii* genotype II by DNA vaccination with recombinant chimeric tachyzoite antigens. Vaccine 2009;27:2489-98.
 160. Jamieson SE, Cordell H, Petersen E, McLeod , Gilbert R, Blackwell JB. Host genetic and epigenetic factors in toxoplasmosis. Mem Inst Oswaldo Cruz 2009;104:162-9.
 161. Jongert E, Roberts CW, Gargano N, Förster-Wald E, Petersen E. Vaccines against *Toxoplasma gondii*: challenges and opportunities. Mem Inst Oswaldo Cruz 2009;104:252-66.
 162. Knudsen JB, Fursted K, Petersen E, Wierup P, Mølgaard H, Poulsen SH, Egeblad H. Infective endocarditis: a continuous challenge. The recent experience of a European tertiary center. J Heart Valve Dis 2009;18:386-94.
 163. Tan HK, Petersen E, Møller LN, Phillips P, Neto EC, Gilbert RE. Effects of storage temperature on detection of *Toxoplasma* IgM in filter paper blood samples and feasibility of retrospective IgM testing of stored Guthrie card blood spots. J Clin Microbiol 2009;47:2626-8.
 164. Schierup Nielsen U, Petersen E, Larsen CS. Hepatitis B Immunization coverage and risk behavior among Danish travelers. Are immunization strategies based on single journey itineraries rational? J. Infect 2009;59:353-9.
 165. Stensvold CR, Møller LN, Skov J, Jensen PM, Kapel CMO, Petersen E, Nielsen HV. Seroprevalence of human toxocariasis in Denmark. Clin Vaccine Immunol 2009;16:1372-3

-
166. Meroni V, Genco F, Tinelli C, Lanzarini P, Bollani L, Stronati M, Petersen E. Treatment with Spiramycin of *Toxoplasma gondii* infection in pregnant women impair the production and the avidity maturation of anti *T. gondii* specific IgG-antibodies. Clin Vaccine Immunol 2009;16:1517-20.
 167. Silveira C, Gargano N, Kijlstra A, Petersen E. Toxoplasma vaccines: appropriate endpoints and sample size in future human clinical trials. Expert Rev Anti-Infect Ther 2009;7:905-8.
 168. Schlagenhauf P, Petersen E. Antimalaria drug resistance: the mono-combi-counterfeit triangle. Exp Rev Anti-Infect Ther 2009;7:1039-42.
 169. Sandfeld L, Petersen E, Sousa S, Laessoe M, Milea D. Bilateral papillitis in ocular toxoplasmosis. Eye. 2010;24:188-9.
 170. Petersen E, Vesco G, Villari S, Buffolano W. What Do We Know About Risk Factors for Infection in Humans with *Toxoplasma gondii* and How Can We Prevent Infections? Zoonosis Publ Hlth 2010;57:8-17.
 171. Röser D, Vedel Nielsen H, Petersen E, Saugmann-Jensen P, Nørgaard-Pedersen B. Congenital toxoplasmosis - A Report on the Danish Neonatal Screening Programme 1999 – 2007. J Inherit Metab Dis. 2010;33(Suppl 2):S241-7.
 172. Petersen E, Mu H, Porsgaard T, Berthelsen LS. Anti-retroviral drugs influence lipid metabolism: a pig model for rapid evaluation new drugs. Antiviral Ther 2010;15:243-51.
 173. Møller LN, Koch A, Petersen E, Hjuler T, Kapel CM, Andersen A, Melbye M. *Trichinella* infection in a hunting community in East Greenland. Epidemiol Infect. 2010;138:1252-6.
 174. Cortina-Borja M, Tan HK, Thulliez P, Paul M, Pollak A, Buffolano W, Malm G, Salt A, Freeman K, Petersen E, Gilbert RE for The European Multicentre Study on Congenital Toxoplasmosis (EMSCOT). Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis. PLoS Med. 2010;7(10). pii: e1000351.
 175. Knudsen JB, Fuursted K, Petersen E, Wierup P, Mølgaard H, Poulsen SH, Egeblad H. Procalcitonin in 759 Patients Clinically Suspected of Infective Endocarditis. Am J Med. 2010;123:1121-7.
 176. Nielsen US, Petersen E, Schade-Larsen C. Hepatitis B immunization coverage and risk behaviour among Danish travellers: Are immunization strategies based on single journey itineraries rational? Response. J Infect. 2010;60:310-1.
 177. Mortensen KL, Knudsen JB, Jensen-Fangel S, Stausbøl-Grøn B, Arendrup MC, Petersen E. Successful management of invasive aspergillosis presenting as pericarditis in an adult patient with chronic granulomatous disease. Mycoses. 2011;54:e233-6.
 178. Stensvold CR, Nielsen HV, Petersen E. Toxocariasis. Ugeskr Laeger. 2011;173:186-9 (Danish).
 179. Yan HK, Yuan ZG, Petersen E, Zhang XX, Zhou DH, He Y, Lin RQ, Xu MJ, Chen LI, Zhong XL, Zhu XG. Vaccination of mice with a recombinant plasmid encoding perforin-like protein 1 against *Toxoplasma gondii*. Exp. Parasitol. 2011;128:38-43.
 180. Tordrup D, Virenfeldt J, Andersen FF, Petersen E. Chimpanzee *Plasmodium ovale* isolated from a patient infected in Ghana: is zoonotic malaria more widespread than previously thought? Malar J. 2011;10:15.
 181. Petersen E, Keld DB, Ellermann-Eriksen S, Gubbels S, Ilkjær S, Jensen-Fangel S, Lindskov C. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. Scand J Infect Dis. 2011;43:495-503.

-
182. Yuan ZG, Zhang XX, He XH, Petersen E, Zhou DH, He Y, Lin RQ, Li XZ, Chen XL, Shi XR, Zhong XL, Zhang B, Zhu XQ. Protective immunity induced by *Toxoplasma gondii* rhostry protein 16 against toxoplasmosis in mice. *Clin Vaccine Immunol.* 2011;18:119-24.
 183. Knudsen JB, Fuursted K, Petersen E, Wierup P, Mølgaard H, Poulsen SH, Egeblad H. Failure of clinical features of low probability endocarditis. The early echo remains essential. *Scand Cardiovasc J.* 2011;45:133-8.
 184. D'Angelillo A, De Luna E, Romano S, Bisogni R, Buffolano W, Gargano N, Del Porto P, Del Vecchio L, Petersen E, Romano MF. *Toxoplasma gondii* Dense Granule Antigen 1 (GRA1) stimulates apoptosis of monocytes through autocrine TGF- β signaling. *Apoptosis.* 2011;16:551-62.
 185. Yuan ZG, Zhang XX, Lin RQ, Petersen E, He S, Yu M, He XH, Zhou DH, He Y, Li HX, Liao M, Zhu XQ. Protective effect against toxoplasmosis in mice induced by DNA immunization with gene encoding *Toxoplasma gondii* ROP18. *Vaccine.* 2011;29:6614-9.
 186. Nielsen US, Thomsen R, Cowan S, Larsen CS, Petersen E. Predictors of travel-related hepatitis A and B: A Danish nationwide case-control study. *J Infect* 2012;64:399-408.
 187. Yan HK, Yuan ZG, Song HQ, Petersen E, Zhou Y, Ren D, Zhou DH, Li HX, Lin RQ, Yang GL, Zhu XQ. Vaccination with a DNA vaccine coding Perforin-like Protein 1 (TgPLP1) and MIC6 Induces Significant Protective Immunity Against *Toxoplasma gondii*. *Clin Vaccine Immunol.* 2012;19:684-9.
 188. Schlagenhauf P, Petersen E. Stand-by emergency treatment (SBET) of malaria in travellers – time to revisit? *Exp Rev anti-Infective Ther.* 2012;10:537-46.
 189. Vase MØ, Hellberg YEK, Larsen CS, Bastien P, Petersen E, Schaumburg H, Bendix K, d'Amore F. Development of a splenic marginal zone lymphoma after several years of chronic visceral leishmaniasis. *Acta Haematol.* 2012;128:20-2.
 190. Petersen E, Kijlstra A, Stanford M. Epidemiology of Ocular Toxoplasmosis. *Ocular Immunology and Inflammation* 2012;20:68-75.
 191. Wang PY, Yuan ZG, Petersen E, Li J, Zhang XX, Li XZ, Li HX, Lv ZC, Cheng T, Ren D, Yang GL, Lin RQ, Zhu XQ. Protective efficacy of a *Toxoplasma gondii* ROP13 plasmid DNA vaccine in mice. *Clin Vacc Immunol* 2012;19:1916-20.
 192. Tesauo C, Juul S, Arnò B, Nielsen CJ, Fiorani P, Frøhlich RF, Andersen FF, Desideri A, Stougaard M, Petersen E, Knudsen BR. Specific detection of topoisomerase I from the malaria causing *P. falciparum* parasite using isothermal rolling circle amplification. *Conf Proc IEEE Eng Med Biol Soc.* 2012:2416-9.
 193. Askling HH, Bruneel F, Buchard G, Castelli F, Chiodini PL, Grobusch MP, Lopez-Vélez R, Paul M, Petersen E, Popescu C, Ramharter M, Schlagenhauf P (ESCMID Study Group on Clinical Parasitology). Management of imported malaria in Europe. *Malar J.* 2012;11:328.
 194. Juul S, Nielsen CJ, Labouriau R, Roy A, Tesauo C, Jensen PW, Harmsen C, Kristoffersen EL, Chiu YL, Frøhlich R, Fiorani P, Cox-Singh J, Tordrup D, Koch J, Bienvenu AL, Desideri A, Picot S, Petersen E, Leong KW, Ho YP, Stougaard M, Knudsen BR. Droplet microfluidics platform for highly sensitive and quantitative detection of malaria-causing *Plasmodium* parasites based on enzyme activity measurement. *ACS Nano ACS Nano.* 2012;6:10676-83.
 195. Petersen E, Severini C, Picot S. *Plasmodium vivax* malaria: a re-emerging threat for temperate climate zones? *Travel Med Infect Dis.* 2013;11:51-9
 196. Schlagenhauf P, Petersen E. Current challenges in travelers' malaria. *Curr Infect Dis Rep.* 2013;15:307-15.
 197. Jalilian B, Christiansen SH, Einarsson HB, Pirozyan MR, Petersen E, Vorup-Jensen T. Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities? *Mol Cell Ther.* 2013;1:2.

-
198. Rosenberg C, Bovin NV, Bram LV, Flyvbjerg E, Erlandsen M, Vorup-Jensen T, Petersen E. Age is an important determinant in humoral and T cell responses to immunization with hepatitis B surface antigen. *Hum Vaccin Immunother*. 2013;9:1466-76.
 199. Yuan ZG, Ren D, Zhou DH, Zhang XX, Petersen E, Li XZ, Zhou Y, Yang GL, Zhu XQ. Evaluation of protective effect of pVAX-TgMIC13 plasmid against acute and chronic *Toxoplasma gondii* infection in a murine model. *Vaccine*. 2013;31:3135-9.
 200. Petersen E, Baekeland S, Memish ZA, Leblebicioglu H. Infectious disease risk from the Syrian conflict. *Intl J Infect Dis*. 2013;17:e666–e7.
 201. Chen J, Huang SY, Li ZY, Yuan ZG, Zhou DH, Petersen E, Zhang NZ, Zhu XQ. Protective immunity induced by a DNA vaccine expressing eIF4A of *Toxoplasma gondii* against acute toxoplasmosis in mice. *Vaccine*. 2013;31:1734-9.
 202. Zhang NZ, Chen J, Wang M, Petersen E, Zhu XQ. Vaccines against *Toxoplasma gondii*: new developments and perspectives. *Expert Rev Vaccines*. 2013;12:1287-99
 203. Kijlstra A, Petersen E. Epidemiology, pathophysiology, and the future of ocular toxoplasmosis. *Ocul Immunol Inflamm*. 2014;22:138-47.
 204. Chen J, Huang SY, Zhou DH, Li ZY, Petersen E, Song HQ, Zhu XQ. DNA immunization with eukaryotic initiation factor-2 α of *Toxoplasma gondii* induces protective immunity against acute and chronic toxoplasmosis in mice. *Vaccine*. 2013;31:6225-31.
 205. Vorup-Jensen T, Rosenberg C, Petersen E. Reply to Shin and Bayry on "An age-related decline of CD62L and vaccine response: a role of microRNA 92a?". *Hum Vaccin Immunother*. 2014;10:1406-7.
 206. Manser M, Granlund M, Edwards H, Saez A, Petersen E, Evengard B, Chiodini P; European Society of Clinical Microbiology and Infectious Diseases Study Group on Clinical Parasitology. Detection of *Cryptosporidium* and *Giardia* in clinical laboratories in Europe--a comparative study. *Clin Microbiol Infect*. 2014;20:O65-71.
 207. Wilson ME, Chen LH, Han PV, Keystone JS, Cramer JP, Segurado A, Hale D, Jensenius M, Schwartz E, von Sonnenburg F, Leder K; GeoSentinel Surveillance Network. Illness in travelers returned from Brazil: the GeoSentinel experience and implications for the 2014 FIFA World Cup and the 2016 Summer Olympics. *Clin Infect Dis*. 2014;58:1347-56.
 208. Chen J, Zhou DH, Li ZY, Petersen E, Huang SY, Song HQ, Zhu XQ. *Toxoplasma gondii*: protective immunity induced by rhoptry protein 9 (TgROP9) against acute toxoplasmosis. *Exp Parasitol*. 2014;139:42-8.
 209. Li ZY, Chen J, Petersen E, Zhou DH, Huang SY, Song HQ, Zhu XQ. Synergy of mIL-21 and mIL-15 in enhancing DNA vaccine efficacy against acute and chronic *Toxoplasma gondii* infection in mice. *Vaccine*. 2014;32:3058-65.
 210. Memish ZA, Assiri A, Alhakeem R, Yezli S, Almasri M, Zumla A, Al-Tawfiq JA, Drosten C, Albarrak A, Petersen E. Middle East respiratory syndrome corona virus, MERS-CoV. Conclusions from the 2nd Scientific Advisory Board Meeting of the WHO Collaborating Center for Mass Gathering Medicine, Riyadh. *Int J Infect Dis*. 2014;24:51-3.
 211. Virenfeldt J, Rudolf F, Camara C, Furtado A, Gomes V, Aaby P, Petersen E, Wejse C. Treatment delay affects clinical severity of tuberculosis: a longitudinal cohort study. *BMJ Open*. 2014;4:e004818.
 212. Petersen E. Open Access publishing. *Int J Infect Dis*. 2014;25:150-1.
 213. Petersen E, Rombo L. Tools for travellers' diarrhoea: bring back the vaccine? *Travel Med Infect Dis*. 2014;12:305-6.

-
214. Chen J, Li ZY, Huang SY, Petersen E, Song HQ, Zhou DH, Zhu XQ. Protective efficacy of *Toxoplasma gondii* calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in mice. BMC Infect Dis. 2014;6:487..
 215. Lu LL, Chen BX, Wang J, Wang D, Ji Y, Yi HG, Chen T, Zhang Y, Petersen E, Li Q, Qu C. Maternal transmission risk and antibody levels against hepatitis B virus e antigen in pregnant women. Int J Infect Dis. 2014;28:41-4.
 216. Jørgensen NP, Meyer RL, Dagnæs-Hansen F, Fuursted K, Petersen E. A modified chronic infection model for testing treatment of *Staphylococcus aureus* biofilms on implants. PLoS One. 2014;9:e103688.
 217. Storm L, Lausch KR, Arendrup MC, Mortensen KL, Petersen E. Vertebral infection with *Candida albicans* failing caspofungin and fluconazole combination therapy but successfully treated with high dose liposomal amphotericin B and flucytosine. Med Mycol Case Rep. 2014;6:6-9.
 218. Klintebjerg K, Petersen E, Pshenichnaya NY, Ermakova LA, Nagorny SA, Larsen CS. Periorbital *Dirofilaria repens* imported to Denmark: A human case report. IDCases. 2014;2:25-6.
 219. Ringqvist Å, Bech P, Glenthøj B, Petersen E. Acute and long-term psychiatric side effects of mefloquine: a follow-up on Danish adverse event reports. Travel Med Infect Dis. 2015;13:80-8.
 220. Petersen E, Pollack MM, Madoff LC. Health-care associate transmission of Middle East Respiratory Syndrome Corona virus, MERS-CoV, in the Kingdom of Saudi Arabia. Int J Infect Dis. 2014;29:299-300.
 221. Petersen E, Chen LH. Reflections on travel-associated infections in Europe. Lancet Infect Dis. 2015;15:6-8
 222. Otte E, Christiansen M, Petersen E. Relapsing Cutaneous Leishmaniasis in a Patient Treated with Humira. Am J Infect Dis. 2015;11:7-10.
 223. Petersen E, Maiga B. Guidelines for treatment of patients with Ebola Virus Diseases are urgently needed. Int J Infect Dis. 2015;30:85-6
 224. Öbrink-Hansen K, Hardlei TF, Brock B, Jensen-Fangel S, Kragh Thomsen M, Petersen E, Kreilgaard M. Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia. Antimicrob Agents Chemother. 2015;59:2398-404.
 225. Chen J, Li ZY, Petersen E, Huang SY, Zhou DH, Zhu XQ. DNA vaccination with genes encoding *Toxoplasma gondii* antigens ROP5 and GRA15 induces protective immunity against toxoplasmosis in Kunming mice. Expert Rev Vaccines. 2015;14:617-24.
 226. Petersen E. Should we offer screening for hepatitis B and other infections to immigrants--legal or illegal? J Travel Med. 2015;22:73-5.
 227. Zumla A, Maeurer M, Marais B, Chakaya J, Wejse C, Lipman M, McHugh TD, Petersen E. Commemorating World Tuberculosis Day 2015. Int J Infect Dis. 2015;32:1-4.
 228. Zumla A, Petersen E, Nyirenda T, Chakaya J. Tackling the tuberculosis epidemic in sub-Saharan Africa--unique opportunities arising from the second European Developing Countries Clinical Trials Partnership (EDCTP) programme 2015-2024. Int J Infect Dis. 2015;32:46-9.
 229. Brinck-Jensen NS, Erichsen P, Tarp B, Lindberg J, Kristensen LH, Erlandsen M, Petersen E, Leutscher PD; InfCare Hepatitis DK group. Clinical findings in a multi-ethnic adult hepatitis B virus patient population in Denmark with emphasis on genotypic characteristics. Scand J Gastroenterol. 2015;50:1032-8.
 230. Petersen E, Hui DS, Perlman S, Zumla A. Middle East Respiratory Syndrome - advancing the public health and research agenda on MERS - lessons from the South Korea outbreak. Int J Infect Dis. 2015;36:54-5.

-
231. Zhang NZ, Xu Y, Wang M, Petersen E, Chen J, Huang SY, Zhu XQ. Protective efficacy of two novel DNA vaccines expressing *Toxoplasma gondii* rhomboid 4 and rhomboid 5 proteins against acute and chronic toxoplasmosis in mice. *Expert Rev Vaccines*. 2015;14:1289-97
 232. Zumla A, Rustomjee R, Ntoumi F, Mwaba P, Bates M, Maeurer M, Hui DS, Petersen E. Middle East Respiratory Syndrome--need for increased vigilance and watchful surveillance for MERS-CoV in sub-Saharan Africa. *Int J Infect Dis*. 2015;37:77-9.
 233. Zumla A, Maeurer M; Host-Directed Therapies Network, Chakaya J, Hoelscher M, Ntoumi F, Rustomjee R, Vilaplana C, Yeboah-Manu D, Rasolof V, Munderi P, Singh N, Aklillu E, Padayatchi N, Macete E, Kapata N, Mulenga M, Kibiki G, Mfinanga S, Nyirenda T, Maboko L, Garcia-Basteiro A, Rakotosamimanana N, Bates M, Mwaba P, Reither K, Gagneux S, Edwards S, Mfinanga E, Abdulla S, Cardona PJ, Russell JB, Gant V, Noursadeghi M, Elkington P, Bonnet M, Menendez C, Dieye TN, Diarra B, Maiga A, Aseffa A, Parida S, Wejse C, Petersen E, Kaleebu P, Oliver M, Craig G, Corrah T, Tientcheu L, Antonio M, Rao M, McHugh TD, Sheikh A, Ippolito G, Ramjee G, Kaufmann SH, Churchyard G, Steyn A, Grobusch M, Sanne I, Martinson N, Madansein R, Wilkinson RJ, Mayosi B, Schito M, Wallis RS. Towards host-directed therapies for tuberculosis. *Nat Rev Drug Discov*. 2015;14:511-2
 234. Chen LH, Petersen E. The era of antibiotic-resistant bacteria--Time for political, travel medicine and healthcare decisions. *Travel Med Infect Dis*. 2015;13:279-80.
 235. Pedersen MG, Jensen-Fangel S, Olesen HV, Tambe SD, Petersen E. Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis. *BMC Infect Dis*. 2015;15:290.
 236. Zumla A, Maeurer M; Host-Directed Therapies Network (HDT-NET) Consortium. Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates. *Clin Infect Dis*. 2015;61:1432-8.
 237. Booth BB, Petersen E. Unusual cause of recurrent fever after travel in South America. *IDCases*. 2015;2:49-52.
 238. Stecher CW, Kallestrup P, Kjetland EF, Vennervald B, Petersen E. Considering treatment of male genital schistosomiasis as a tool for future HIV prevention: a systematic review. *Int J Public Health*. 2015;60:839-48.
 239. Zumla A, Azhar EI, Arabi Y, Alotaibi B, Rao M, McCloskey B, Petersen E, Maeurer M. Host-directed therapies for improving poor treatment outcomes associated with the Middle East Respiratory Syndrome coronavirus infections. *Int J Infect Dis*. 2015;40:71-4.
 240. Snipsøyr MG, Ludvigsen M, Petersen E, Wiggers H, Honoré B. A systematic review of biomarkers in the diagnosis of infective endocarditis. *Int J Cardiol*. 2016;202:564-70.
 241. Elachola H, Assiri A, Turkestani AH, Sow SS, Petersen E, Al-Tawfiq JA, Memish ZA. Advancing the global health security agenda in light of the 2015 annual Hajj pilgrimage and other mass gatherings. *Int J Infect Dis*. 2015;40:133-4.
 242. Zhang NZ, Wang M, Xu Y, Petersen E, Zhu XQ. Recent advances in developing vaccines against *Toxoplasma gondii*: an update. *Expert Rev Vaccines*. 2015;14:1609-21.
 243. Öbrink-Hansen K, Jensen-Fangel S, Brock B, Hardlei TF, Adelfred A, Nejatbakhsh Y, Kragh Thomsen M, Petersen E. Piperacillin/tazobactam continuous infusion at 12G/1.5G per day in CF patients results in target plasma-concentrations. *J Cyst Fibros*. 2016;15:e13-4.
 244. Brinck-Jensen NS, Vorup-Jensen T, Leutscher PD, Erikstrup C, Petersen E. Immunogenicity of twenty peptides representing epitopes of the hepatitis B core and surface antigens by IFN- γ response in chronic and resolved HBV. *BMC Immunol*. 2015;16:65.
 245. Chen J, Li ZY, Petersen E, Liu WG, Zhu XQ. Co-administration of interleukins 7 and 15 with DNA vaccine improves protective immunity against *Toxoplasma gondii*. *Exp Parasitol*. 2016;162:18-23.

-
246. Gotfred-Rasmussen H, Lund M, Enemark HL, Erlandsen M, Petersen E. Comparison of sensitivity and specificity of 4 methods for detection of *Giardia duodenalis* in feces: immunofluorescence and PCR are superior to microscopy of concentrated iodine-stained samples. *Diagn Microbiol Infect Dis*. 2016;84:187-90.
247. Petersen E, Wilson ME, Touch S, McCloskey B, Mwaba P, Bates M, Dar O, Mattes F, Kidd M, Ippolito G, Azhar EI, Zumla A. Rapid Spread of Zika Virus in The Americas - Implications for Public Health Preparedness for Mass Gatherings at the 2016 Brazil Olympic Games. *Int J Infect Dis*. 2016;44:11-5.
248. Zumla A, Saeed AB, Alotaibi B, Yezli S, Dar O, Bieh K, Bates M, Tayeb T, Mwaba P, Shafi S, McCloskey B, Petersen E, Azhar EI. Tuberculosis and mass gatherings-opportunities for defining burden, transmission risk, and the optimal surveillance, prevention, and control measures at the annual Hajj pilgrimage. *Int J Infect Dis*. 2016;44:pii: S1201-9712.
249. Zumla A, Goodfellow I, Kasolo F, Ntoumi F, Buchy P, Bates M, Azhar EI, Cotten M, Petersen E. Zika virus outbreak and the case for building effective and sustainable rapid diagnostics laboratory capacity globally. *Int J Infect Dis*. 2016;45:92-4.
250. Ntoumi F, Kaleebu P, Macete E, Mfinanga S, Chakaya J, Yeboah-Manu D, Bates M, Mwaba P, Maeurer M, Petersen E, Zumla A. Taking forward the World TB Day 2016 theme 'Unite to End Tuberculosis' for the WHO Africa Region. *Int J Infect Dis*. 2016;46:34-7.
251. Jørgensen NP, Skovdal SM, Meyer RL, Dagnæs-Hansen F, Fursted K, Petersen E. Rifampicin-containing combinations are superior to combinations of vancomycin, linezolid and daptomycin against *Staphylococcus aureus* biofilm infection in vivo and in vitro. *Pathog Dis*. 2016;74:pii: ftw019.
252. Al-Abri SS, Petersen E. Crimean-Congo hemorrhagic fever - A ticking bomb? *Travel Med Infect Dis*. 2016;14:71-2.
253. Aitsi-Selmi A, Murray V, Heymann D, McCloskey B, Azhar EI, Petersen E, Zumla A, Dar O. Reducing risks to health and wellbeing at mass gatherings: the role of the Sendai framework for Disaster Risk Reduction. *Int J Infect Dis*. 2016;47:101-4.
254. Huang SY, Jensen MR, Rosenberg CA, Zhu XQ, Petersen E, Vorup-Jensen T. In silico and in vivo analysis of *Toxoplasma gondii* epitopes by correlating survival data with peptide-MHC-I binding affinities. *Int J Infect Dis*. 2016;48:14-9.
255. Petersen E, Zumla A. To have sepsis or to be septic - is the difference between these clinical conditions important? *Int J Infect Dis*. 2016;48:118-9.
256. Atabani SF, Wilson S, Overton-Lewis C, Workman J, Kidd IM, Petersen E, Zumla A, Smit E, Osman H. Active screening and surveillance in the United Kingdom for Middle East respiratory syndrome coronavirus in returning travellers and pilgrims from the Middle East: a prospective descriptive study for the period 2013-2015. *Int J Infect Dis*. 2016;47:10-4.
257. Debrah P, Nettey H, Miltersen KK, Ayeh-Kumi P, Brock B, Sarkodie J, Akwo-Kretchy I, Owusu-Danso P, Adjei S, Petersen E, Hardlei TF. Artemether-Lumefantrine Concentrations in Tablets and Powders from Ghana Measured by a New High-Performance Liquid Chromatography Method. *Am J Trop Med Hyg*. 2016;95:158-63.
258. Shafi S, Dar O, Khan M, Khan M, Azhar EI, McCloskey B, Zumla A, Petersen E. The annual Hajj pilgrimage-minimizing the risk of ill health in pilgrims from Europe and opportunity for driving the best prevention and health promotion guidelines. *Int J Infect Dis*. 2016;47:79-82.
259. Zumla A, McCloskey B, Bin Saeed AA, Dar O, Al Otabi B, Perlmann S, Gautret P, Roy N, Blumberg L, Azhar EI, Barbeschi M, Memish Z, Petersen E. What is the experience from previous mass gathering events? Lessons for Zika virus and the Olympics 2016. *Int J Infect Dis*. 2016;47:1-4.

-
260. Zumla A, Dar O, Kock R, Muturi M, Ntoumi F, Kaleebu P, Eusebio M, Mfinanga S, Bates M, Mwaba P, Ansumana R, Khan M, Alagaili AN, Cotten M, Azhar EI, Maeurer M, Ippolito G, Petersen E. Taking forward a 'One Health' approach for turning the tide against the Middle East respiratory syndrome coronavirus and other zoonotic pathogens with epidemic potential. *Int J Infect Dis*. 2016;47:5-9.
261. Blumberg L, Regmi J, Endricks T, McCloskey B, Petersen E, Zumla A, Barbeschi M. Hosting of mass gathering sporting events during the 2013-2016 Ebola virus outbreak in West Africa: experience from three African countries. *Int J Infect Dis*. 2016;47:38-41.
262. Öbrink-Hansen K, Wiggers H, Bibby BM, Hardlei TF, Jensen K, Marianne Kragh MK, Brock B, Petersen E. Penicillin G treatment in infective endocarditis patients – does standard dosing result in therapeutic plasma concentrations? *Basic Clin Pharmacol Toxicol* 2017;120:179-86.
263. Ansumana R, Keitel S, Roberts GMT, Ntoumi F, Petersen E, Ippolito G, Zumla A. Impact of Infectious Disease Epidemics on Tuberculosis Diagnostic, Management and Prevention Services: Experiences and Lessons from the 2014-2015 Ebola Virus Disease Outbreak in West Africa. *Intl J Infect Dis* 2017;56:101-4.
264. Mohsin J, Al Khalili S, Gerrits van den Ende AHG, Khamis F, Petersen E, de Hoog S, Meis JF, Al-Hatmi AMS. Imported Talaromycosis in Oman in Advanced HIV: A Diagnostic Challenge Outside the Endemic Areas. *Mycopathologia*. 2017;182:739-45.
265. Sow F, Bonnot G, Ahmed BR, Diagana SM, Kebe H, Koita M, Samba BM, Al-Mukhaini SK, Al-Zadjali M, Al-Abri SS, Ali OA, Samy AM, Hamid MM, Ali Albsheer MM, Simon B, Bienvenu AL, Petersen E, Picot S. Genetic diversity of *Plasmodium vivax* metacaspase 1 and *Plasmodium vivax* multi-drug resistance 1 genes of field isolates from Mauritania, Sudan and Oman. *Malar J*. 2017;16:61.
266. Petersen E, Mohsin J. Should travelers be screened for multi-drug resistant (MDR) bacteria after visiting high risk areas such as India? *Travel Med Infect Dis*. 2016;14:591-4.
267. Schlagenhauf P, Gautret P, Rodriguez-Morales AJ, Jones ME, Toovey S, Petersen E, Chen LH. Drug resistant pathogens and travel: No road map but a new initiative from Travel Medicine and Infectious Disease. *Travel Med Infect Dis*. 2016;14:543-5.
268. Petersen E, Khamis F, Migliori GB, Bay JG, Marais B, Wejse C, Zumla A. De-isolation of patients with pulmonary tuberculosis after start of treatment - clear, unequivocal guidelines are missing. *Int J Infect Dis*. 2017;56:34-8.
269. Petersen E, Maeurer M, Marais B, Migliori GB, Mwaba P, Ntoumi F, Vilaplana C, Kim K, Schito M, Zumla A. World TB Day 2017: Advances, Challenges and Opportunities in the "End-TB" Era. *Int J Infect Dis*. 2017;56:1-5.
270. Linguissi LS, Gwom LC, Nkenfou CN, Bates M, Petersen E, Zumla A, Ntoumi F. Health systems in the Republic of Congo: challenges and opportunities for implementing tuberculosis and HIV collaborative service, research, and training activities. *Int J Infect Dis*. 2017;56:62-7.
271. Al-Abri SS, Abaidani IA, Fazlalipour M, Mostafavi E, Leblebicioglu H, Pshenichnaya N, Memish ZA, Hewson R, Petersen E, Mala P, Nhu Nguyen TM, Rahman Malik M, Formenty P, Jeffries R. Current status of Crimean-Congo haemorrhagic fever in the World Health Organization Eastern Mediterranean Region: issues, challenges, and future directions. *Int J Infect Dis*. 2017;58:82-9.
272. Jørgensen NP, Hansen K, Andreasen CM, Pedersen M, Fursted K, Meyer RL, Petersen E. Hyperbaric Oxygen Therapy is Ineffective as an Adjuvant to Daptomycin with Rifampicin Treatment in a Murine Model of *Staphylococcus aureus* in Implant-Associated Osteomyelitis. *Microorganisms*. 2017;5(2).pii: E21.
273. Stecher CW, Sacko M, Madsen H, Wilson S, Wejse C, Keita AD, Landouré A, Traoré MS, Kallestrup P, Petersen E, Vennervald B. Anemia and growth retardation associated with *Schistosoma haematobium* infection in Mali: a possible subtle impact of a neglected tropical disease. *Trans R Soc Trop Med Hyg*. 2017;111:144-53.

-
274. Simon B, Sow F, Al Mukhaini SK, Al-Abri S, Ali OAM, Bonnot G, Bienvenu AL, Petersen E, Picot S. An outbreak of locally acquired *Plasmodium vivax* malaria among migrant workers in Oman. *Parasite*. 2017;24:25.
275. Schlagenhauf P, Petersen E, Grobusch MP. Travellers' Malaria - Horizons 202X. *Travel Med Infect Dis*. 2017;17:1-2.
276. Mohsin J, Pál T, Petersen E, Darwish D, Ghazawi A, Ashraf T, Sonnevend A. Plasmid-mediated colistin resistance gene *mcr-1* in an *Escherichia coli* ST10 bloodstream isolate in the Sultanate of Oman. *Microb Drug Res* 2017;24:278-82.
277. Zumla A, Brian McCloskey B, Endericks T, Azhar E, Petersen E. The Challenges of Cholera at the 2017 Hajj pilgrimage. *Lancet Infect Dis*. 2017;17:895-7.
278. Hargreaves S, Nellums LB, Ravensbergen SJ, Friedland JS, Stienstra Y on behalf of the ESGITM Working Group on Vaccination in Migrants (Nick Beeching, Francesco Castelli, Marie Norredam, Hakan Leblebicioglu, Hakan Erdem, Manuel Carballo, Christoph Lange, Delia Goletti, Christian Wejse, Ozaras R, Lopez-Velez R, Tsakris A, E Petersen, Civljak R, Patrica Schlagenhauf). Divergent approaches in the vaccination of recently arrived migrants to Europe: a survey of national experts. *Euro Surv Euro Surveill*. 2018;23(41).
279. Ravensbergen SJ, Nellums LB, Hargreaves S, Stienstra Y, Friedland JS ESGITM Working Group on Vaccination in Migrants. National approaches to the vaccination of recently arrived migrants in Europe: A comparative policy analysis across 32 European countries. *Travel Med Infect Dis*. 2019;27:33-8.
280. Dam Larsen F, Jespersen S, Wejse C, Petersen E, Larsen CS. One-sixth of inpatients at a Danish infectious disease ward have imported diseases: a cross-sectional analysis. *Trav Med Infect Dis* 2017;20:43-8.
281. Christiansen SH, Murphy RA, Juul-Madsen K, Fredborg M, Hvam ML, Axelgaard E, Skovdal SM, Meyer RL, Sørensen UBS, Möller A, Nyengaard JR, Nørskov-Lauritsen N, Wang M, Gadjeva M, Howard KA, Davies JC, Petersen E, Vorup-Jensen T. The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills Gram-negative Bacteria. *Sci Rep*. 2017;7(1):15653.
282. Petersen E, Petrosillo N, Koopmans M; ESCMID Emerging Infections Task Force Expert Panel. Emerging Infections are an increasingly important topic. *Clin Microbiol Infect*. 2017;24:369-75.
283. Petersen E, Blumberg L, Wilson ME, Zumla A. Ending the Global Tuberculosis Epidemic by 2030-The Moscow Declaration and achieving a Major Translational Change in Delivery of TB Healthcare. *Int J Infect Dis*. 2017;65:156-8.
284. Yezli S, Assiri A, Nabulsi H, Awam A, Blumberg L, Endericks T; Stergachis A, Reicher S, McCloskey B, Petersen E, Alotaibi B. From mass gatherings medicine to mass gatherings health: Conclusions from the 3rd International Conference on Mass Gatherings Medicine, Riyadh, Kingdom of Saudi Arabia. *Int J Infect Dis*. 2018;66:128-30.
285. Stecher C, Wilson S, Landouere A, Wejse C, Traoré M, Sacko M, Petersen E, Vennervald BJ, Kallestrup P, Keita AD, Madsen H. Organomegaly in Mali before and after praziquantel treatment. A possible association with *Schistosoma haematobium*. *Heliyon*. 2017;3:e00440.
286. Clemente WT, Pierrotti LC, Abdala E, Morris MI, Azevedo LS, López-Vélez R, Cuenca-Estrella M, Torre-Cisneros J, Petersen E, Camargo LFA, Wright AJ, Beeching NJ, Vilela EG, Santoro-Lopes G, Len O, Stucchi RSB, Manuel O, Faria LC, Leblebicioglu H, Huprikar S, Molina I, Mourão PHO, Kotton CN, Aguado JM; working group on Endemic Disease and Travel Medicine in Solid-Organ Transplantation. Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America. *Transplantation*. 2018;102:193-208.
287. Pierrotti LC, Levi ME, Di Santi SM, Segurado AC, Petersen E. Malaria Disease. Recommendations for Solid Organ Transplant Recipients and Donors. *Transplantation*. 2018;102(2S Suppl 2):S16-26.

-
288. Hede MS, Fjelstrup S, Lötsch F, Zoleko RM, Klicpera A, Groger M, Mischlinger J, Endame L, Veletzky L, Neher R, Simonsen AKW, Petersen E, Mombo-Ngoma G, Stougaard M, Ho YP, Labouriau R, Ramharter M, Knudsen BR. Detection of the Malaria causing Plasmodium Parasite in Saliva from Infected Patients using Topoisomerase I Activity as a Biomarker. *Sci Rep*. 2018;8:4122.
289. Tiberi S, Petersen E, Maeurer M, Ntoumi F, Yeboa-Manu D, Mwaba P, Vilaplana C, Dar O, Bates M, Corrah T, Rao M, Kapata N, Azhar EI, Memish ZA, Mfinanga S, Aseffa A, Ippolito G, Migliori GB, Zumla A. Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 - "Wanted: Leaders for a TB-Free World. You can make history. End TB". *Int J Infect Dis*. 2018;68:122-4.
290. Zumla A, Azhar EI, Hui DS, Shafi S, Petersen E, Memish ZA. Global spread of antibiotic-resistant bacteria and mass-gathering religious events. *Lancet Infect Dis*. 2018;18:488-90.
291. Mahdi AS, Molai M, Chandwani J, Al Khalili H, Ibrahim H, Pandak N, Khamis F, Petersen E. Late onset acute pancreatitis in *P. falciparum* malaria – an adverse reaction to intravenous artesunate ? *ID Cases* 2018;12:124-6.
292. Pshenichnaya N, Petersen E, Patel D, Gautret P, Schlagenhauf P. Football fever in Russia: Infectious disease risks and the FIFA world cup 2018. *Travel Med Infect Dis*. 2018;24:4-6.
293. Skovdal SM, Pedersen Jørgensen N, Petersen E, Jensen-Fangel S, Ogaki R, Zeng G, Johansen MI, Wangd M, Rohde H, Meyer RL. Ultra-dense PLL-g-PEG coating reduces *Staphylococcus epidermidis* biofilms on medical implants and improves antibiotic treatment outcome. *Acta Biomaterialia* 2018;76:46-55.
294. Mahdi AS, Al-Khalili SM, Chung CC, MMolai M, Hashim Ibrahim H, Petersen E, Khamis F, Pandak N. Scrub typhus complicated by ARDS, myocarditis and encephalitis imported to Oman from Nepal. *Oman Med J* 2019;34:254-6.
295. Al Balushi A, Khamis F, Klaassen CHW, Robert-Gagneux J-P, van Hellemond JJ, Petersen E. Double infection with *Leishmania tropica* and *L. major* in an HIV patient controlled with high doses of Amphotericin B. *Open Furum Infect Dis* 2018;5:ofy323.
296. Zumla A, Petersen E. The Historic and Unprecedented United Nations General Assembly High Level Meeting on Tuberculosis (UNGA-HLM-TB) - 'United to End TB - An Urgent Global Response to a Global Epidemic'. *Int J Infect Dis*. 2018 Sep 19. pii: S1201-9712(18)34535-1. doi: 10.1016/j.ijid.2018.09.017. [Epub ahead of print] No abstract available.
297. Javelle E, Al Balushi A, Jespersen S, Al-Abri S, Gautret P, Petersen E. Should travellers be offered vaccination against the dengue virus? *Travel Med Infect Dis*. 2019;27:2-4.
298. Lee SS, Petersen E. Overcoming 'purview paradox' to make way for the effective implementation of PrEP in preventing HIV transmission. *Int J Infect Dis*. 2018;77:105-6.
299. Petersen E, Abubakar I, Ihekweazu C, Heymann D, Ntoumi F, Blumberg L, Asogun D, Mukonka V, Lule SA, Bates M, Honeyborne I, Mfinanga S, Mwaba P, Dar O, Vairo F, Mukhtar M, Kock R, McHugh T, Ippolito G, Zumla A. Monkeypox - Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era. *Int J Infect Dis*. 2018;78:78-84.
300. Bay-Richter C, Petersen E, Liebenberg N, Elfving B, Wegener G. Latent toxoplasmosis aggravates anxiety- and depressive-like behaviour and suggest a role of gene-environment interactions in the behavioural response to the parasite. *Behav Brain Res*. 2019;364:133-9.
301. Petersen E, Chakaya J, Ippolito G, Jawad FM, Zumla A. Latent Tuberculosis Infection - diagnostic tests and deciding when to treat. *Lancet Infect Dis* 2019;19:231-3.
302. Petersen E, Chakaya J, Jawad FM, Ippolito G, Zumla A. High-income countries and latent tuberculosis infection screening for migrants - Authors' reply. *Lancet Infect Dis*. 2019;19:691-2.

303. Purpari G, Macaluso G, Di Bella S, Gucciardi F, Mira F, Di Marco P, Lastra A, Petersen E, La Rosa G, Guercio A. Molecular characterization of human enteric viruses in food, water samples, and surface swabs in Sicily. *Int J Infect Dis.* 2019;80:66-72.
304. Petersen E, Rao M, Ippolito G, Gualano G, Chakaya J, Moore DAJ, Gaskell K, Öhd JN, Hergens MP, Krishnamoorthy S, Ugarte-Gil C, Kirwan DE, Honeyborne I, McHugh TD, Köser CU, Kranzer K, Tiberi S, Migliori GB, Mao Q, Yang Y, de Oliveira SP, Cardoso RF, Detjen A, Marais B, de Gijssel D, von Reyn CF, Goscé L, Abubakar I, Maeurer M, Zumla A. World Tuberculosis Day March 24th 2019 Theme: "It's TIME" - International Journal of Infectious Diseases Tuberculosis Theme Series. *Int J Infect Dis.* 2019;80S:S1-5.
305. Petersen E, Kantele A, Koopmans M, Asogun D, Ihekweazu C, Zumla A. Human Monkeypox – Epidemiological and Clinical characteristics, Diagnosis and Prevention. *Infectious Disease Clinics of North America* 2019;33:1027-43.
306. Al Farsi F, Chandwani J, Mahdi AS, Petersen E. Severe imported malaria in an intensive care unit: A Case Series. *Severe imported malaria in an intensive care unit: A case series.* *IDCases.* 2019;17:e00544.
307. Skovdal SM, Christiansen SH, Johansen KS, Viborg O, Bruun NH, Jensen-Fangel S, Holm IE, Vorup-Jensen T, Petersen E. Inhaled nebulized glatiramer acetate against Gram-negative bacteria is not associated with adverse pulmonary reactions in healthy, young adult female pigs. *PLoS One* 2019;14(10):e0223647.
308. Al-Abri SS, Kurup PJ, Al Manji A, Al Kindi H, Al Wahaibi A, Al Jardani A, Mahmoud OA, Al Balushi L, Al Rawahi B, Al Fahdi F, Al Siyabi H, Al Balushi Z, Al Mahrooqi S, Al Manji A, Al Sharji A, Al Harthi K, Al Abri B, Al-Raidan A, Al Bahri Z, Al-Mukhaini S, Amin M, Prasanna AR, Petersen E, Al Ajmi F. Control of the 2018-2019 dengue fever outbreak in Oman, a country previously without local transmission. *Int J Infect Dis.* 2019; 90:97-103.
309. Petersen E, Gradoni L, McLellan S. Human Genetics Influence the Susceptibility to Cutaneous Leishmaniasis Caused by *Leishmania guyanensis*. *Clin Infect Dis.* 2019 Nov 13. pii: ciz812.
310. Petersen E, Memish ZA, Zumla A; Al Maani A. Transmission of respiratory tract infections at mass gathering events. *Cur Opin Pulm Med: In press (invited review).*
311. Snipsøyr MG, Wiggers H, Ludvigsen M, Stensballe A, Vorum H, Hvitfeldt Poulsen S, Rasmussen LM, Petersen E, Honoré B. Towards identification of novel putative biomarkers for infective endocarditis by serum proteomic analysis, Submitted
312. Yaquobi F, Al Rawahi B, Ndunda N, Al Abri B, Al Jardani A, Al Maqbali A, Petersen E, Al Abri S. Screening migrants from tuberculosis high endemic countries for latent TB in a low endemic setting. Submitted

Posters have not been listed

Books

Petersen E (Editor), Chen LH (co-editor), Schlagenhaut P (co-editor). *A Geographical Guide to Infectious Diseases.* Wiley & Sons. 2nd edition in press. April 2017.

Petersen E (Editor), Chen LH (co-editor), Schlagenhaut P (co-editor). *A Geographical Guide to Infectious Diseases.* Wiley & Sons. 1 st Edition. London May 2011.

Petersen E. & Ambrose-Thomas, P. (Eds.) *Congenital toxoplasmosis. Scientific background, clinical management and control.* Springer Verlag (Paris) 2000.

Book chapters

1. Perlmann P, Berzins K, Kabilan L, Perlmann H, Troye-Blomberg M, Wåhlin B, Björkman A, Høgh B, Petersen E, Patarroyo EM. Humoral and cellular immune response to the C-terminal amino

-
- acid repeats of Pf 155, a potential vaccine candidate of the human malaria parasite, *Plasmodium falciparum*. IN: Vaccines-87, Cold Spring Harbour Laboratories, New York 1987,86-91.
2. Lebech M, Petersen E. The design of a study for neonatal screening of congenital toxoplasmosis in Denmark. In: New Trends in Neonatal Screening. Takasugi, N. & Naruse, H. (Eds.). p. 149-151. Hokkaido University Press, Sapporo 1994.
 3. Nielsen, HV, Innes EA, Petersen E, Buxton D. Strategies for development of vaccines against *Toxoplasma gondii*. In: Petersen, E. & Ambroise-Thomas, P. (Eds.) Congenital toxoplasmosis. Scientific background, clinical management and control. Springer Verlag (Paris). 2000:313-322.
 4. Petersen E, Eaton, RB. Neonatal screening for congenital infection with *Toxoplasma gondii*. In: Petersen E & Ambroise-Thomas P (Eds.) Congenital toxoplasmosis. Scientific background, clinical management and control. Springer Verlag (Paris), 2000:307-311.
 5. Petersen E, Dubey JP. Biology of Toxoplasmosis, In: *Clinical Toxoplasmosis: Prevention and Management*, D. H. M. Joynson & T. G. Wreghitt (Eds.). pp. 1-42. Cambridge University Press, Cambridge 2001.
 6. Petersen E. Biology and pathogenesis in *Toxoplasma gondii* infections. In: Akuffo, H., Linder, E., Ljungström, I., Wahlgren, M (Eds.) Parasites of the Colder Climates. Taylor & Francis. London 2003
 7. Petersen E & Liesenfeld O. Clinical signs and diagnosis of *Toxoplasma gondii*. In: Kim K & Weiss L. *Toxoplasma gondii* – the model apicomplexan. Academic Press. UK. 2007
 8. Petersen E. Epidemiology, Diagnostics and chemotherapy. In: Ajioka J & Soldati D (Eds.) The Biology of *Toxoplasma gondii*. Horizon Scientific Press. UK. 2007.
 9. Petersen E, Thiebault R, Leroy V, Salmi R, Gilbert R. Public Health aspects of *Toxoplasma gondii* infections in pregnant women and newborn children. In: Encyclopedia of Public Health. Elsevier. Elsevier, UK. 2008.
 10. Eskild Petersen. Human Toxoplasma Infection. IN: *Toxoplasma gondii*. The Model Apicomplexan ---Perspectives and Methods. Louis M. Weiss and Kami Kim (Eds). Academic Press, New York, 2009.
 11. Petersen, E. & Liesenfeld, O. Toxoplasmosis. IN: Oxford Textbook of Medicine. Oxford University Press. 2009, 2010, 2011.
 12. Schlagenhauf P. & Petersen E. Prevention of malaria. IN: Treatment and Prevention of Malaria, Henry M. Staines and Sanjeev Krishna (Eds.). Series Milestones in Drug Therapy. Birkhauser Publishing, Basel, Switzerland, 2011.
 13. Evengard B, Marcinkute A, Petersen E. Northern Europe. In: Petersen E, Chen LH, Schlagenhauf P. (Eds.) A Geographical Guide to Infectious Diseases. Wiley 2011.
 14. Lutwick LI, Mendelson M, Petersen E. Diagnostic Methods in Infectious Diseases. In: Petersen E, Chen LH, Schlagenhauf P. (Eds.) A Geographical Guide to Infectious Diseases. Wiley 2011 and 2017
 15. Liesenfeld, O. & Petersen, E. Toxoplasmosis. IN: Oxford Textbook of Medicine. Oxford University Press. 2012, 2017, 2018
 16. McLeod R, Tubbergen C van, Montoya JG, Petersen E. Human Toxoplasma Infection. IN: Louis M. Weiss and Kami Kim (Eds.). *Toxoplasma gondii*: The Model Apicomplexan ---Perspectives and Methods. Elsevier, Amsterdam, 2013.
 17. Petersen E, Gomez-Marin J, Mandelbrot L. Toxoplasmosis. In: International Encyclopedia of Public Health, Second Edition, Elsevier Scientific, Amsterdam 2017.
 18. Patricia Schlagenhauf, Mary E. Wilson, Eskild Petersen Anne McCarthy, Lin H. Chen, Malaria chemoprophylaxis. Chapter 15 IN: Jay S. Keystone, Dr. Phyllis E. Kozarsky, Dr. David O.
-

Freedman, Dr. Hans D. Nothdruff, and Dr. Bradley A. Connor, Travel Medicine. 3rd edition, Elsevier Scientific, Amsterdam 2018.

WHO documents

- 1 Lyng, J., Pettersen, E., Petersen, E. An international standard for anti-toxoplasma IgG and IgM antibodies. WHO working document WHO/BS/92.1692.
- 2 Hansen, G.A., Lyng, J., Petersen, E. Calibration of a replacement preparation for the second international standard for anti-toxoplasma serum, human. WHO Expert Committee on Biological Standardisation. WHO/BS/94.1761.

Opponent at PhD thesis

Thomas Greve. Diagnosing patients with community-acquired pneumonia: improvement through PCR analysis and a teaching intervention. University of Aarhus, Denmark. Chairman, evaluation committee. Scheduled for 8th June 2012.

Kirill Gromov. Osteoclastic Bone Resorption in Chronic Osteomyelitis. Faculty of Health Science, University of Aarhus, Denmark. 2009.

Alvydas Malakaukas. Molecular epidemiology of trichinellosis in Lithuania and biological characteristics of *Trichinella* genotypes in rat. Royal Veterinary University, Copenhagen. 2002.

Thelma S. Okey. Étude de la kystigenese de *Toxoplasma gondii* chez le rat immunocompetent ou immunodeprime et dans un modele d'infection congenitale. Characterisation genotypique de differentes souches et clones toxoplasmiques par amplification aleatoire. Département de Parasitologie-Mycologie Médicale et Moléculaire, Faculté de Médecine, Université Joseph Fourier, Grenoble, France.

Hervé Pelloux. Production de cytokines par des monocytes-macrophages et par des cellules d'astrocytome d'origine humaine apres infection par *Toxoplasma gondii*: étude de Tumor Necrosis Factor Alpha, de l'interleukine 1 Alpha et de l'interleukine 6. Département de Parasitologie-Mycologie Médicale et Moléculaire, Faculté de Médecine, Université Joseph Fourier, Grenoble, France.

Supervisor for PhD students

- | | |
|-----------------|---|
| 2020 (expected) | <u>Sandra Marie Skovgaal</u> . In vitro and in vivo effect of ultradense polyethylene glycol coating on foreign bodies to prevent the formation of biofilms. The iNANO Center, University of Aarhus, Faculty of Health Sciences. |
| 2018 | <u>Charlotte Stecher</u> , MD. Scistosomiasis in Mali. A comparative study of different parziquantel schedules. In collaboration with the University of Bamako and University of Copenhagen. |
| 2016 | <u>Phillip Debra</u> , MSc. Improving efficacy of malaria treatment and diagnosis. Supported by Danida, BSU (Building stronger Universities) programme in collaboration with the Faculty of Health Sciences, University of Ghana, Accra, Ghana. |
| 2016 | <u>Kristina Öbrink-Jensen</u> . Antibiotic treatment assessment and optimization through therapeutic drug monitoring. With co-suprvision from Birgitte Broch, Department of Biochemistry, Aarhus University Hospital and Søren Fangel-Jensen, Department of Infectious Diseases, Aarhus University Hospital, Denmark. |

-
- 2016 Nis Pedersen Jørgensen. Staphylococcal biofilm infections on orthopedic implants: the importance of various regulatory genes on biofilm expression and its interaction with different antibiotics. Submitted to the faculty of Health Science November 2010 for an MD-PhD grant. In collaboration with Kurt Fuursted, Department of Clinical Microbiology, Aarhus University Hospital Skejby and Rikke Meyer, iNANO, Faculty of Science, University of Aarhus.
- 2012 Carina Rosenberg. Immunity to chronic intracellular microorganisms: clinical and experimental studies of *Toxoplasma gondii* and hepatitis B virus Faculty of Health Science, University of Aarhus, Denmark. 2009. In collaboration with Thomas Vorup, Institute of Medical Microbiology and Immunology, Aarhus University (handed in to the faculty the 28.9.2012).
- 2011 Ulla Schierup Nielsen. Risk of hepatitis A and B in travellers. In collaboration with the Department of Epidemiology, Statens Serum Institut, Copenhagen.
- 2010 Jane Byriel Knudsen. Infectious Endocarditis. Current problems in management and diagnosis. In collaboration with Dr Henrik Egebjerg, Department of Cardiology, Aarhus University Hospital, Skejby. Started 2006.
- 2006 Lone Møller. Human *Trichinella* infections in Greenland (in collaboration with Professor Christian Kapel, Royal Veterinary School, Copenhagen and Professor Mads Melby, Department of Epidemiology Research, Statens Serum Institut, Copenhagen. 4 November 2006.
- 2005 Dorte Remmer Schmidt. Congenital toxoplasmosis in Denmark. University of Copenhagen. 25 November 2005.
- 2002 Henrik Vedel Nielsen. The Development of DNA-vaccines against HIV and *Toxoplasma gondii*. University of Copenhagen. 2002.
- 1999 Kim P. David. The control of Malaria in pregnancy by impregnated bed nets. A community study from Sierra Leone. University of Aarhus, Denmark, 1999.
- 1995 NuahnT. Marbiah. Control of malaria by impregnated bed nets and regular chemosuppression in an area with holoendemic malaria. (In collaboration with Professor David Bradley, London School of Hygiene and Tropical Medicine), 1995.
- Visiting professor Visiting Professor, Department of Infectious Diseases, University of Brescia, Italy. WHO Collaborating Center on Migration and Travel Medicine.
15 May – 16 June 2018, invited by Professor Francesco Castelli.
- Invited expert reviews
- 2012 Ministry of Education, Rome, Italy. External evaluation of research activities at Italian Universities.
- 2010, 2011 Invited reviewer for INSERM, France.
- 2009 International Foundation for Science, IFS. IFS is a non-governmental organization which supports promising young scientists from developing countries to do research in such countries.
-

2006	DLR-Project Management Agency, Deptment of Health Research, of the German Federal Ministry of Education and Research (BMBF).
2003	External scientific reviewer for the Austrian Medical Research Council.
2003	External scientific reviewer for the Wellcome Foundation, UK
2002	Chariman, international committee evaluating the Center for Experimental Parasitology appointed by the dean at the Royal School of Veterinary Medicine, Copenhagen, Denmark.
2000	Chaiman, National Reference Group on Malaria Prophylaxis in Travellers. National Board of Health. External scientific reviewer for the Czech Medical Research Council.
2001	National Institute of Health, NIH, National Eye Institute. Konsulent opgave omkring bekæmpelse og kontrol af okulær Toxoplasmose.
1999	External scientific reviewer fro the Czech Medical Research Council.
1999 - 2000	Expert reviewer, malaria and tuberculosis. The 5th Framework Programme, EU. Key Action 2 "Control of Infectious Diseases" (June 1999, January 2000, December 2000).
1998 - 1999	Invited member of a advisory group on Toxoplasma and food safety, Centers of Diseases Control, Atlanta, United States.
1997	External reviewer for the Ministère de l'Enseignement Supérieur et de la Recherche", Paris, France.
1993	Expert adviosr to the EU-mission, Pakistan, on EU support for the national malaria control program.

Major research grants and research projects

27.	2018	I am currently developing the SEVTRAV project (Severe infections in returning travellers) for GeoSentinel. We have assured collaboration with the Erasmus Medical center, Rotterdam; 27 GS centers have expressed interest and next phase is development of a detailed protocol, ethical approval nd funding.
26	2015	Genetic characterization of <i>Plasmodium vivax</i> malaria in Oman. ESCMID grant 30,000 €.
25.	2013	Sino-Danish Vaccine Symposium 28 – 30 June, Health, Aarhus University. Danish Medical Research Council 250,000 Dkr in collaboration with Mogens Kilean, Uffe Skov Sørensen and Thomas Vorup-Jensen.
24.	2012	Participate in a collaborate project on developing a new malaria diagnostic tool based on microfluidics and malaria specific topoisimerate enzyme activity. Leading scientist Birgitta Knudsen. Supported by 3.5 mil. Dkr by East-Jutland Innovation.
23.	2011	Gene delivery for gene therapy in cystic fibrosis. 4.8 mil. DKR (€ 645,000) Targeting the Aha1 gene by siRNA encapsulated in chotosan. Danish Strategic Research Council in collaboration with Professor Jørgen Kjems, Institute of Molecular Biology, Aarhus University.
22.	2010	Establishing collaboration with a research group at Guangzhou Veterinary University and Southern China School of Tropical Medicine

-
- and Public Health on the development of vaccines using *Toxoplasma gondii* as a model. One year post doc grant from the Danish Medical Research council, 50,000€.
21. 2010 Prevention of hepatocellular carcinoma by treatment of chronic hepatitis B and C using nanoparticle-based gene transfection of dendritic cells. 650,000 DKr in collaboration with Thomas Vorup Jensen, Institute of Medical Microbiology and Immunology, Faculty of Health Science, University of Aarhus.
 20. 2009 One year PhD grant for Ulla Schierup Nielsen for her studies on hepatitis A and B in travellers.
 19. 2009 Development of experimental vaccines against *Toxoplasma gondii*. PhD project for Carina Rosenberg, BSc. University of Aarhus. 635.000 DKK.
 18. 2008 ERC Advanced Grant 2008 (ERC-2008-AdG, proposal no. 232818: Development of generic vaccines based on genome wide expression of ORFs using *Toxoplasma gondii* as a model) med karakteren 4,63 ud af 8. Panelet skrev bl.a.: The applicant has a strong record in the area of malaria and toxoplasmosis, The principle investigator has a good track-record and the proposal is of good scientific value.
 17. 2006 Cytotoxic T lymphocytes and dendritic cells in HIV infections. University of Aarhus. 400.000 DKK.
 16. 2005 Metabolic side effects of anti-retroviral treatment in a porcine Institute of Clinical Medicine, University of Aarhus. 100.000 DKK.
 15. 2002 – 2005 Epidemiologi af *Trichinella* infections in Grønland. Commission for Scientific studies in Greenland. 1.5 mio. DKK.
 14. 2004 – 2005 Meta-analysis of cohorts of children with congenital toxoplasmosis identified by pre- and neonatal screening. NIH, USA, 100.000 USD in collaboration with the Institute of Child Health, London.
 13. 1996 - 2004 Identification of genetic markers for mother to child transmission of *Toxoplasma gondii*. The study is a part of the European Multicentre Study on Congenital Toxoplasmosis and is performed in collaboration with Professor Jenefer Blackwell, Cambridge Institute for Medical Research, Cambridge, UK.
 12. 2002 – 2005 European Consensus Conference on Congenital Toxoplasmosis. 5th Framework Programme, EU, 300,000 €. In collaboration with Dr Ruth Gilbert, Institute of Child Health, London, and Professor Roger Salamon ISPED, Université de Bordeaux, France
 11. 2000 - 2003 European Multicentre Study of Congenital Toxoplasmosis - II (EMSCOT - II). Coordinator. Dr Ruth Gilbert, Institute of Child Health, London, EU, 5th Framework Programme, 640,000 €.
 10. 1999-2002 Malaria Control in pregnant women in Ghana. Coordinator Dr Kim David, Danida, 1.5 mio. DKK
 9. 1997-2000 European Multicentre Study on Congenital Toxoplasmosis. EU, 4th Framework Programme. 405,000 €
 8. 1998 - 2001 Diagnosis and typing of *Mycobacterium tuberculosis* in the Baltic countries. EU INCO-COPERNICUS 300.000 DKK.
 7. 1996 - 1998 European Study Group on Congenital Toxoplasmosis. EU BIOMED III 300,000 €
-

-
6. 1994 - 1996 Field trial of impregnated bed nets and Maloprim in West African children (Sierra Leone), Part II. EU STDIII 300,000 €. The project was closed due to the civil war in Sierra Leone.
 5. 1993 - 1998 Identification of virulence factors in *Toxoplasma gondii*. A joint project with Dr med vet Peter Lind, Danish Veterinary Institute, Copenhagen. National Medical and Veterinary Research Councils. 1.5 mio DKK.
 4. 1993 - 1996 The influence of impregnated bed nets on the outcome of pregnancy in an area with holoendemic malaria (Sierra Leone). DANIDA 1.5 mil. DKK.
 3. 1993 - 1995 European Study Group on Congenital Toxoplasmosis. EU BIOMED1, 293,000 €
 2. 1991 - 1994 Field trial of impregnated bed nets and Maloprim in West African children (Sierra Leone). EU, Science and Technology for Development 550,000 €
 1. 1989 - 1991 Health Surveillance and Rice Farming in Eastern Liberia. 6th European Development Fund 594,000 US\$. The project was closed due to the civil war in Liberia.

Invited international talks and teaching at international courses and workshops

- 1997 Centers for Disease Control, CDC, Atlanta U.S.A.:
Food Safety, Toxoplasma in pregnant women in Europe
- 2000 National Institute of Health, Bethesda, U.S.A.
Symposium of Toxoplasma eye disease
Preliminary results of the EMSCOT collaboration
- 2003 World Congress of Nephrology, Berlin, Tyskland
Malaria vaccines, current trends
- 2005 ECCMID, Copenhagen, Danmark
Congenital Toxoplasmosis in Europe and Toxoplasmosis in Immunocompromised patients.
- 2005 John Hopkins School of Medicine, Stanley Neurovirology Laboratory, Indianapolis, U.S.A.
Stanley Meeting on Toxoplasma Infection
Population based studies of Toxoplasma infection in Europe
- 2006 Current Topics in Infectious Diseases, Grindelwald, Switzerland
(www.ewi.med.uu.nl/CTID/10112005CTID2006.pdf)
Virulence of *Toxoplasma gondii* in humans, and
Prevention and treatment of neonatal infections
- European Society for Clinical Microbiology and Infectious Diseases,
Annual Meeting, Nice, France
Congenital Toxoplasmosis in Europe
- Paul-Ehrlich-Gesellschaft. 20 Jahrestagung, Bonn 14 – 16 september.
The effectiveness of therapeutic regimens for the prevention of Toxoplasma-infections.
- ICOPA XI, International Congress on Parasitology, Glasgow 6 – 11 August 2006.
Parasitic infections in pregnant women

- Northern European Congress on Travel Medicine, Edinburgh, 7-10 June
New drugs against malaria; pandemic influenza
- 2007 International Meeting on Emerging Diseases and Surveillance, IMED, Wien, 23 – 25 februar, 2007.
Emerging Parasitic Infections
- International Congress on Congenital Toxoplasmosis. ACIN – Centro de Investigaciones Biomedicas- Universidad del Quindio. Columbia. 13 – 16 May 2007.
Vaccines against Toxoplasma gondii, current status.
- National Congress on Infectious Diseases. Torino, Italy 21 – 22 June
Imported malaria to Europe and rapid diagnosis of malaria.
- International Congress on infections in Immuncompromised Children Cambridge, England, 6 – 7 December
Toxoplasma gondii infection in the immunocompromised host.
- 2008 Toxoplasmosis: 100 years later. Pavia, Italien 27 – 28 marts, 2008.
Toxoplasma vaccines
- Kolloquium Infektiologie und Mikrobiologie
Klinik für Infektionskrankheiten, Universitätsspital, Zürich.
24 april, 2008.
Toxoplasmosis in pregnancy: Recent trends
- International congress on infectious Diseases
Kuala Lumpur, Malaysia, 18 – 21 juni, 2008.
Update in emerging parasitic infections.
- 2009 European Congress on Clinical Microbiology and Infectious Diseases ECCMID, Chairman, Educational workshop on emerging parasitic infections.
Opisthorchis and Fasciola in Russia and former SU countries
- ESCMID course on infectedions in pregnancy and the neonate.
Bertinoro, Italy:
Congenital Toxoplasmosis
- 2010 2nd Annual world Conference on Vaccines, Beijing 24-26 March, 2010, and School of Public Health and Tropical Medicine, Southern China Medical university, Guangzhou:
Invited speaker:
Future vaccines against Apicomplexan parasites with Toxoplasma gondii as the model
- European Congress on Clinical Microbiology and Infectious Diseases ECCMID, Vienna 10-13 April. Invited speaker.
Management of severe and complicated influenza H1N1
- Northern European Conference on Travel Medicine. Hamburg 26 – 29 May. Chairman, session on:
Rapid infectious disease surveillance systems
- International Conference on Clinical Toxoplasmosis, Marseille, France
Invited speaker. 20 – 22 October.
Vaccines against Toxoplasma
- Course of Perinatal Infections, University of Barcelona, Spain. 26 November. Invited speaker.
Screening for congenital Toxoplasma, pro's and con's.

- 2011
- 3rd Annual world Conference on Vaccines, Beijing, 3rd – 5th March, Invited speaker:
Strategies to treat chronic hepatitis B infections
- ECCMID, Milano, 7th – 10th May. Invited speaker
Management of severe malaria
Controversies in management of intestinal parasites
- ESCMID basic parasitology course, Ankara, Turkey
Malaria, Parasitology case stories
- National Conference of Tropical and Travel Medicine Bucharest, Romania, 4th – 5th November. Invited speaker
Management of Severe Malaria
Case stories in Tropical Medicine
- 2012
- 22nd ECCMID, London, UK, 31st March-3rd April 2012,
Meet-the-Expert. Travel medicine - where is it going?
- 2nd Annual Symposia on Parasitology Guangzhou, China, 30th July - 1st August 2012
Malaria in Europe, past and present
- 50th year anniversary. Department of Tropical Medicine and Parasitology, Poznan University Hospital. 24th September
The risk of reintroducing P. vivax in Europe
- National Conference on Infectious Diseases, 26 – 28 Sept. Bucarest, Romania
Oral treatment of infectious endocarditis, and Management of malaria
- ESCMID Postgraduate course 16 – 18 Nov. Istanbul, Turkey
Investigation of the returning febrile traveller
- 2013
- IFoTox-2013. Interdisciplinary Forum on Toxoplasmosis 14 – 16 March, 2013. Tübingen, Germany
Congenital Toxoplasmosis – the challenge of early diagnosis
- EKMUD, 20-24 March, Antalya, Tyrkey
Fever in returning travellers
- EKMUD, 20-24 March, Antalya, Tyrkey
Fever in returning travellers
- 23rd ECCMID, 27-30 April, Berlin, Germany
Screening for congenital toxoplasmosis - pros and cons^{5th} Eurasia Congress of Infectious Diseases, 15-18th May, Tirana
European guidelines for the Management of malaria and Investigating febrile patients with a travel history
- ESCMID Technical Workshop for Basic and Clinical Parasitology 17 - 21 June 2013, Porto, Portugal
Malaria, Parasitology case stories
- ESCMID postgraduate course. Infectious Diseases in Pregnant Women, Fetuses and Newborns. 29 Sept. – 03 Oct., Bertinoro, Italy
Malaria in pregnancy and newborns

- 2014
- ICID (International Conference on Infectious Diseases), 1-4th April, Cape Town, South Africa.
How to get your paper published. Meet the Editor-in-Chief of the International Journal of Infectious Diseases.
- ECCMID, Barcelona 10 – 13 May
Tracking down toxoplasmosis
- Barcelona Institute for Global Health, 15th May
What determine risk of reintroducing P.vivax malaria in temperate climate zones
- ICOPA; Mexico City, August 10 – 15th
Challenges for control of congenital toxoplasmosis in South America
Vaccines against T.gondii, what can we achieve in South America?
- ESCMID Postgraduate course 22 – 24 Sep.
Izmir, Turkey
Course co-organizer and
Malaria: epidemiology and risk of resurgence.
- Asian Pacific Conference on Pediatric Infectious Diseases
Beijing 5 – 8 October
Haemolysis after Artemisinin treatment of malaria
Epidemiology of congenital toxoplasmosis
- 2015
- Oman International Conference on Infectious Diseases
Muscat 7th and 8th February 2015
HIV, natural history and future challenges
Bone Infection, diagnosis and management
- Advancing Travel Medicine in Oman, Muscat 14 – 15 February
The ABC of Vaccination and malaria prophylaxis
Preventing and investigating travellers' diarrhea
Vaccines for low incidence, high impact diseases
- ESCMID Postgraduate course 22 – 24 Sep.
Izmir, Turkey
Course organizer and
Malaria: epidemiology and risk of resurgence
- 7th Eurasia Congress of Infectious Diseases (EACID) September 30 and October 3^d, Tbilisi, Georgia.
Stop malaria in returning travelers
- ESCMID Postgraduate course 20 – 21 Nov.,
Beijing, China
Microbiology for Diagnosis of Infectious Diseases: ABC and XYZ
Course co-organizer
New methods in diagnostic parasitology and parasitology case stories
- 2016
- International Congress on Infectious Diseases 2 – 5 March
Hyderabad, India
How to get your paper published
- ESCMID Postgraduate course 17 – 19 March
Al Ain, UAE
New methods in malaria diagnosis
Parasitology cases

-
- ESCMID Summer School 2 – 8 July
Sevilla, Spain
New methods in diagnostic parasitology
- ESCMID Postgraduate course on Infections in the pregnant mother and newborn child 25 – 29 Sept.
Bertinoro, Italy
Malaria in pregnancy
- 2017 ESCMID Postgraduate course on Hospital Acquired Infections
22 – 24 March
Muscat, Oman
Co-organizer
Antibiotics stewardship – is it too late ?
- Refugee Health, Palermo, Italy. An ESCMID post graduate workshop.
October 3rd.
Screening arriving refugees for malaria – is it necessary?
- 3rd International Conference on Mass Gatherings Medicine
23-25 October 2017, Ministry of Health, Riyadh, Saudi Arabia
Surveillance of emerging infections using informal networks
- Gulf Patient safety Conference, 25 – 26 October, Dubai
Malaria risk from blood transfusion
- 2018 ICID, International Conference of Infectious Diseases, 1 – 4 March
2018, Buenos Aires.
How to get your study published – meet the editor of the IJID
- Migrant Health, ESCMID Workshop, 8 – 10 March, Muscat Oman.
Modalities for health promotion and risk communication for migrants, e.g. CCHF and malaria
- Diploma course in tropical medicine for physicians, Bernhard Nocht Institute for Tropical Medicine, 30 June – 1 July 2018. Hamburg, Germany.
Infectious disease challenges in the Middle East
- IMED - International Meeting on Emerging Diseases and Surveillance
9 – 12 November 2018, Vienna (Organizer ProMED and ISID).
Clinical challenges associated with emerging infections
- 2019 ID-week Dubai 24 – 26 April, 2019
Vaccine hesitancy and immunizations in pregnancy.
- Emerging Infections. ESCMID course, Florence, 13 – 15 May
Returning travellers as sentinels for emerging infections
- ID-week Abu Dhabi, 24 – 26 October, 2019
The measles epidemic and Antibiotic Stewardship
- Annual meeting of the Russian Federation of Tuberculosis specialists
Moscow 13 November 2019.
Diagnosis and management of latent tuberculosis.
- 2020 Annual meeting of the Danish Society for Cardiology 18
March 2020, Århus University Hospital
Main speaker: *Danish contribution to the diagnosis and management of infectious endocarditis.*

Administrative and organisational experience

Revision of the candidate part of the medical studies, Faculty of Health Science, Aarhus University

2008-2009 Participated in working group 3 "Consistency and Continuity".

Editorial work

2012 - Editor-in-chief. International Journal of Infectious Diseases.

2012 - Associate editor. Travel Medicine and Infectious Diseases

2010 - 2012 Member of editorial board, Journal of Clinical Microbiology, American Association of Clinical Microbiology.

2011 - 2012 Member of the editorial board, Expert Review of Anti-Infective Therapy

2011 - 2012 Member of the editorial board, Current Infectious Disease Reports, a journal published by Springer.

2005 - 2015 Editor, Danish Drug Information Catalogue (Lægemiddelkataloget; www.lmk.dk/) responsible for anti-parasitic drugs and vaccines except childhood vaccines.

1999 - Co-Editor (Moderator) on parasitic diseases. ProMED (www.promedmail.org). ProMED is a global, electronic news service reporting outbreaks of infectious diseases. ProMED is a programme under the International Society of Infectious Diseases, Harvard School of Medicine.

Scientific committees

2017 - Co-chair with Nicola Petrisillo a new ESCMID Task force on emerging infections

2012 - 2018 Member of the Educational Sub-committee, ESCMID. The committee oversee and approve all ESCMID postgraduate training activities.

2009 - 2011 Program Committee member. European Conference on Clinical Microbiology and Infectious Diseases, ECCMID.

2007 - 2011 Scientific Secretary, Working Group on Clinical Parasitology, European Society of Clinical Microbiology and Infectious Diseases, ESCMID.

2011 - 2015 Member of the board, Working Group on Clinical Parasitology, European Society of Clinical Microbiology and Infectious Diseases, ESCMID.

Biotech advisory board member

2010 - Member of advisory board for the French biotech company "VitamFero", Evry, France, which work with vaccine development with *Toxoplasma gondii* as the model organism.

Referee for scientific journals

Acta Neurologica Scandinavica
Acta Tropica
American Journal of Gynecology and Obstetrics
American Journal of Ophthalmology
American Journal Tropical Medicine & Hygiene

APMIS
 Applied and Environmental Microbiology
 Archives Diseases in Childhood
 BMC Infectious Diseases
 BMC Paediatrics
 BMC Public Health
 British Journal of Gynaecology and Obstetrics (BJOG)
 British Journal of Ophthalmology
 Clinical Immunology and Immunopathology
 Clinical Infectious Diseases
 Clinical Microbiology and Infection
 Clinical and Vaccine Immunology
 Emerging Infectious Diseases
 European Journal of Microbiology and Infectious Diseases
 Expert Opinion on Investigational Drugs
 Expert Opinion anti-Infective Therapy
 Infection and Immunity
 International Journal of Parasitology
 JAMA (Journal American Medical Association)
 Journal of Clinical Microbiology
 Journal of Infectious Diseases
 Journal of Medical Microbiology
 Journal of Travel Medicine
 Lancet
 Lancet Infectious Diseases
 Malaria Journal
 OIE Scientific and Technical Review
 Parasite Immunology
 Pediatric Infectious Disease Journal
 Scandinavian Journal of Infectious Diseases
 Therapy
 Travel Medicine and Infectious Disease
 Ugeskrift for Læger
 Vaccine

Scientific societies, membership

1976 -	Royal Society of Tropical Medicine and Hygiene
1976 -	Danish Society for Tropical Medicine and International Health
1985 -	Danish Society for Infectious Diseases
1989 -	Danish Society for Parasitology
1992 -	Scandinavian Society for Parasitology
1995 -	Danish Society for Clinical Microbiology
1997 -	Danish Society for Travel Medicine
1997 -	European Society for Clinical Microbiology and Infectious Diseases
1998 -	Danish Society for Quality Assurance in Health Care
1999 -	American Society for Microbiology
2003 -	Infectious Disease Society of America

International meetings, member or chairman of the organising committee

January	1992	Congenital Toxoplasmosis. European seminar to prepare application to EU 2nd Framework Programme. National Medical Research Council.
September	1994	Parasitic Zoonoses. Joint Baltic-Scandinavian symposium, Vilnius. Lithuania, 6 - 8 September 1994.

September	1995	Chairman. Biological Standards in Serological assays. A joint meeting between the WHO Expert Committee on Biological Standardisation and Statens Serum Institut.
May	1998	Scandinavian Congress on Travel Medicine, Stockholm
May	2000	Scandinavian Congress on Travel Medicine, Bergen, Norway.
June	2000	European Congress on Congenital Toxoplasmosis. Vienna, Austria. Chairman, organizing committee.
June	2003	International Toxoplasma Conference, Copenhagen. Chairman of organizing committee.
May	2004	Scandinavian Congress on Travel Medicine, Stockholm. Member of organizing committee.
October	2005	European Toxoplasma Consensus Conference, EUROTOXO Bordeaux, France. Member of organizing committee.
May	2006	Toxoplasma and Food (http://www.pa.izs.it/toxofood/) Istituto Zooprofilattico Sperimentale della Sicilia, Palermo, Italy. Member of organizing committee.
June	2007	Northern European Congress of Travel Medicine. Edinburg, United Kingdom. Member of organizing committee.
September	2008	Toxoplasma Centenary Congress, Buzio, Brazil. Chairman, international organizing Committee.
October	2010	International Conference on Clinical Toxoplasmosis, Marseille, France. Member of the organizing committee.
November	2012	The febrile traveller. A postgraduate course by ESCMID. Member of the organizing committee.
October	2014	Emerging infections in the Mediterranean and Middle East. Izmir, An ESCMID post graduate workshop.
November	2015	Update on new diagnostic methods in microbiology. Beijing. An ESCMID post graduate workshop.
March	2017	Hospital Acquired Infections. Muscat, Oman. An ESCMID post graduate workshop.
May	2017	CISTM15, Barcelona. Member of the Scientific Program Committee.
March	2018	Migrant Health, Muscat, Oman. An ESCMID post graduate workshop. (proposed not yet granted)
October	2018	Migrant Health, Rome, Italy. An ISTM conference. Member of the International scientific Board.

Consultant for Connect-Denmark

2002 - 2009

Connect Denmark is a non-profit organisation offering expert advice to new start-up companies. Coonect assist in developing business plans and identify potential investors through so called "Springboards"

Danish Maritime Authority

1999 – 2003 Consultancy on malaria prevention and prophylaxis for seafarers. I developed a strategy based on prophylaxis in high risk ships, like coastal traffic in tropical Africa and kit for self diagnostics in the medical kit.

Danish Armed Forces

2000 - Consultant on prevention of infectious diseases and in particular malaria prophylaxis. Prepared data that allowed the armed forces to stop giving troops malaria prophylaxis in Iraq. Advisor on malaria prophylaxis.

2010, 2012 June. Two day course in Infectious Diseases and Tropical Medicine for medical staff physicians and auxiliary staff). Skalstrup airforce base, Roskilde.

2013, 2014, 2015 Tropical Medicine. Course organizer. Two week Postgraduate training course for army physicians.
Skalstrup airforce base, Roskilde, Denmark

2014 – 15 Member of the Ebola evacuation team, Danish Airforce.
Participated in Ebola evacuation mission 5 – 7 March, Freetown, Sierra, Leone.

Quality control and accreditation

1995 - I have since April 1995 been Assessor for SWEDAC (Swedish Board for Accreditation and Conformity Assessment), where I have participated in the accreditation of 14 department of clinical microbiology, and courses on the implementation of standards EN45001 and ISO17025. I am a member of SWEDAC's reference group for clinical microbiology.

2000 - Ekspert, Danish Medical Devices Certification, an organisation under Dansk Standard approving medical devices according to the EU In Vitro Diagnostics directive.

2002 Assessor. DANAK, Danish Accreditation Authority

2002 SWEDAC theoretical course in ISO17025 in clinical microbiology.

2004 Consultant for DEKS (Danish External Quality Assurance) on molecular diagnostic methods in microbiology.

2007 Responsible for quality control and assurance at the Department of infectious Diseases and responsible for accreditation of the department after the Danish national standard (IKAS).

2008 SWEDAC. Course in implementation of the ISO17025 standard in Clinical Microbiology, SWEDAC.Borås, Sweden, 23 – 26 october.

2009 Responsible for the accreditation process at the department of infectious diseases, Aarhus University Hospital Skejby under the DDKM (Den Danske Kvalitets Model) standard.

During my employment at Statens Serum Institut, I had the responsibility for accreditation of the department of Mycobacterial and Parasitic infections after the EN45001 standard in 1996 and the Department of Gastrointestinal and Parasitic Infection after ISO17025 in 2002.